

Review

2-Phenethylamines in Medicinal Chemistry: A Review


Carlos T. Nieto, Alejandro Manchado, Leland Belda, David Diez and Narciso M. Garrido



<https://doi.org/10.3390/molecules28020855>

Review

2-Phenethylamines in Medicinal Chemistry: A Review

Carlos T. Nieto , Alejandro Manchado, Leland Belda , David Diez  and Narciso M. Garrido * 

Department of Organic Chemistry, Faculty of Chemical Sciences, University of Salamanca, Pl. Caídos, s/n, 37008 Salamanca, Spain

* Correspondence: nmg@usal.es

Abstract: A concise review covering updated presence and role of 2-phenethylamines in medicinal chemistry is presented. Open-chain, flexible alicyclic amine derivatives of this motif are enumerated in key therapeutic targets, listing medicinal chemistry hits and appealing screening compounds. Latest reports in discovering new bioactive 2-phenethylamines by research groups are covered too.

Keywords: 2-phenethylamine; medicinal chemistry; ligands; adrenoceptors; carbonyl anhydrase; dopamine receptor; DAT; 5-HT; MAO; PPAR; sigma receptors; TAAR1

1. Introduction

The 2-phenethylamine motif is widely present in nature, from simple, open-chain structures to more complex polycyclic molecular arrangements. The importance of this moiety is probably best exemplified by the endogenous catecholamines dopamine, norepinephrine and epinephrine (an example of open-chain 2-phenethylamines), exhibiting a central role in dopaminergic neurons, which play a critical role in voluntary movement, stress or mood [1]. Several naturally occurring alkaloids, i.e., morphine, (*S*)-reticuline or berberine, embedded in the 2-phenethylamine unit form more complex cyclic frameworks derived from its natural biosynthetic pathways (Figure 1).



Citation: Nieto, C.T.; Manchado, A.; Belda, L.; Diez, D.; Garrido, N.M. 2-Phenethylamines in Medicinal Chemistry: A Review. *Molecules* **2023**, *28*, 855. <https://doi.org/10.3390/molecules28020855>

Academic Editor: Jean-Yves Winum

Received: 22 December 2022

Revised: 10 January 2023

Accepted: 11 January 2023

Published: 14 January 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).




Figure 1. Examples of naturally occurring biologically active compounds displaying a 2-phenethylamine scaffold.

Additionally, in addition to their prominent therapeutic applications, it is worth mentioning the recreational use of a long list of alkaloids incorporating the aforementioned moiety (“designer drugs”) [2], responsible for drug abuse-related conditions [3–8]. Surprisingly, the literature lacks a comprehensive summary that bundles up 2-phenethylamine-based structures and known therapeutic targets, including basic hits or advanced leads. Pairing these will present an appealing opportunity to both new and experienced researchers to summarize

2-phenethylamines target binding and therapeutic scope, as well as selectivity/antitarget issues. Considering all these, a review covering the medicinal chemistry landscape is presented here as a brief, central resource linking up 2-phenethylamine hits and receptors. From the structural point of view, 2-phenethylamines present a vast therapeutic chemical space, not just as is, but considering different substitutions, functional group decorations, ring enclosures or heteroaromatic analogues. Describing such a massive quantity of scaffolds with the phenethylamine resemblance is beyond the scope of this review and more, such asly requires a dedicated book. For this reason, the present review covers only structures where there is an alicyclic amine (Figure 2, blue examples), clustering them all under the 2-phenethylamine label. The authors believe that such cases as 2-heteroaryl ethylamines or cyclic amines, despite presenting 2-phenethylamine resemblance, represent other categorized entities (i.e., tetrahydroisoquinolines or 3-phenyl-pyrrolidines examples) on their own, worth independent review (Figure 2, red examples). This review also covers those 2-phenethylamines where the phenyl ring is condensed with a heteroaryl ring, as the primary motif ring is a phenyl one.




Figure 2. Description of 2-phenethylamine scope of the present review.

This review is divided in sections covering those molecular targets where 2-phenethylamines were found to be biologically relevant. Medicinal chemistry leads and state-of-the-art research on novel molecules are described here.

2. 2-Phenethylamine Targets of Biological Importance

2.1. Adenosine Receptors

Adenosine receptors family are G-protein-coupled receptors (GPCR) widely distributed in human body tissue. They have four members, named A_1 , A_{2A} , A_{2B} and A_3 , with well-reported activities in mediating inflammation, cardiovascular vasodilation or central and peripheral nervous system pathological responses [9–12].

The 2-phenethylamine moiety may be found in a range of AR (adenosine receptors) ligands, such as *N*6-(2-phenylethyl)adenosine (**1**) [13], APNEA (*N*6-[2-(4-aminophenyl)ethyl]adenosine) (**2**) [14,15], CGS 21680 (**3**) [16–19] or ZM241385 (**4**) [20–22]. Murai et al. synthesized photoreactive CGS 21680 derivatives comprising photophores, such as benzophenone **5** or phenylazide **6** for photoaffinity labeling (Figure 3). This allows elucidation of the functional analysis of adenosine receptor A_{2A} through competitive binding assays against [3 H]-NECA (*N*-ethyladenosine-5'-uronamide) [23].




Figure 3. 2-Phenylethyl-based AR ligands.

2.2. α -Adrenergic Receptors

Another class of GPCR targeted by 2-phenethylamines are constituted by α -adrenergic receptors (or α -adrenoceptors). There are two main groups of α -adrenergic receptors, α_1 and α_2 , with several subtypes within (α_{1A} , α_{1B} , α_{1D} , α_{2A} , α_{2B} , α_{2C}). Group α_1 is distributed in cardiovascular, intestinal, CNS and urinary systems, while group α_2 is located in pancreas, CNS, and cardiovascular regions as well [24].

Probably the best representatives of the 2-phenethylamine chemical space are the endogenous catecholamines L-DOPA (7), dopamine (8), norepinephrine (9) (noradrenaline) and epinephrine (10) (adrenaline), biosynthetically produced in cascade from phenylalanine (11)/tyrosine (12) naturally occurring amino acids (Figure 4).




Figure 4. Catecholamine biosynthetic pathways.

Based on these catecholamines, several studies were performed to investigate the effect of chirality, further functionalization, and activity on different derivatives [25–31]. This later triggered the elaboration of many derivatives conserving the 2-phenylethyl moiety, which have been frequently used in the context of medicinal chemistry as tool compounds (Figure 5, Table 1).

Table 1. α -Adrenergic medicinal chemistry leads.

Molecule	Name	Primary Targets	Secondary Targets	References
13	D2343	α_1	β_2 -adrenoceptor	[32]
14	Dobutamine	α_1	β_1 , β_2 -adrenoceptors	[33–35]
15	Etilefrine	α_1	AMP-activated protein kinase (AMPK)	[36]
16	HEAT (BE2254)	α_1		[37–39]
17	Labetalol	α_1	β -adrenoceptors	[40]
18	Methyldopa	α_2		[41,42]
19	OPC-28326	α_2		[43,44]
20	Phenylephrine	α_1		[45,46]
21	Silodosin	α_1		[47,48]
22	Synephrine	α_1	β -adrenoceptors	[49,50]
23	Tamsulosin	α_1		[51]
24	Ulimorelin	α_1	Ghrelin receptor (GRLN)	[52]




Figure 5. 2-Phenylethyl-based α -adrenergic medicinal chemistry leads.

2.3. β -Adrenergic Receptors

Close to the previously described α -type, the β -adrenergic receptors are also activated by catecholamines norepinephrine and epinephrine. There are three receptor subtypes (β_1 , β_2 and β_3) that are implicated in diverse cardiovascular and pulmonary functions [53,54], leading to a vast ligand chemical space (Figure 6, Table 2) to treat cardiogenic shock, heart failure, asthma, overactive bladder (agonists), arrhythmias, hypertension (antagonists commonly known as beta blockers) [55].

Table 2. β -Adrenergic medicinal chemistry leads.

Molecule	Name	Primary Targets	Secondary Targets	References
25	Amibegron	β_3		[56,57]
26	Arbutamine	β		[58–60]
27	Bambuterol	β		[61]
28	Batefenterol	β_2	Muscarinic M2, M3	[62,63]
29	BI-167107	β_2		[64]
30	BRL 37344 sodium	β_3		[65]
31	Brombuterol	β		[66]
32	Bromchlorbuterol	β		[67]
33	CL 316243	β_3		[68,69]
34	Clenproperol	β_2		[70]
35	Clorprenaline	β_2		[71]
36	Denopamine	β_1		[72]
37	Dopexamine	β_2		[73]
38	Epanolol	β		[74]
39	Fenoterol	β_2		[75,76]
40	Guanfacine	β_1	α_2 -adrenoceptors	[77]
41	HOKU-81	β_2		[78]
42	Imoxiterol	β		[79]
43	Indacaterol	β		[80]
44	Isoprenaline	β		[81–83]

Table 2. Cont.

Molecule	Name	Primary Targets	Secondary Targets	References
45	Isoxsuprine	β	N-methyl-D-aspartate (NMDA)	[84]
46	KUC-7322	β_3		[85]
47	KUL-7211	β		[86]
48	L748337	β_3		[87]
49	L755507	β_3		[88]
50	Levalbuterol	β_2		[89]
51	Lubabegron	β		[90]
52	LY377604	β_3		[91]
53	Mapenterol	β_2		[92]
54	Metaproterenol	β_2		[93,94]
55	Mirabegron	β_3		[95]
56	N-5984	β_3		[96]
57	Naminterol	β_2		[97]
58	Navafenterol	β_2	Muscarinic M3	[98]
59	Octopamine	β		[99,100]
60	Olodaterol	β_2		[101,102]
61	Pamatolol	β		[103]
62	PF-610355	β_2		[104,105]
63	Phenylethanolamine A	β		[106]
64	Pronethalol	β		[107]
65	Reproterol	β_2	Phosphodiesterase (PDE)	[108]
66	Ritodrine	β_2		[109]
67	Ro 363	β_1		[110]
68	Rotigotine	β	α_2 -adrenoceptor, 5-HT _{1A} , Dopamine D2, D3, D4, D5	[111]
69	Salbutamol	β_2		[112]
70	Salmeterol	β_2		[113]
71	SB-206606	β_3		[114]
72	Sibenadet	β	Dopamine D2	[115]
73	Solabegron	β_3		[116]
74	Sulfinalol	β		[117]
75	Synephrine	β	α -adrenoceptor	[118]
76	Talibegron	β_3		[119]
77	TD-5471	β_2		[120]
78	Terbutaline	β_2		[121,122]
79	Tulobuterol	β_2		[123]
80	Vilanterol	β		[124,125]
81	Zinterol	β_2		[126]
82	ZK-90055	β_2		[127]
83	-	β_3		[128]
84	-	β_3		[129]




Figure 6. Cont.




Figure 6. Cont.




Figure 6. 2-Phenylethyl-based β -adrenergic medicinal chemistry leads.

2.4. Aldose Reductase

ALR2 aldose reductase is an enzyme of the polyol pathway responsible for the transformation of glucose into sorbitol, with relevant involvement in long-term diabetic complications. A series of modified 2-phenethylamines **85** comprising the insertion of aliphatic chains, aromatic rings or carboxylic acids were elaborated by Sun et al. [130]. This resulted in the obtention of a small library of derivatives with low inhibition effects towards in vitro pig kidney ALR2 (Figure 7).




Figure 7. 2-Phenylethyl-based ALR2 ligands by Sun et al [130].

2.5. Carbonic Anhydrase

Carbonic anhydrases (CAs) are Zn-based (also Fe-based) metalloenzymes present across all living organisms of the different life kingdoms. Divided in eight different families (α , β , γ , δ , ϵ , ζ , η , θ , and t types), they catalyze the hydration of carbon dioxide to bicarbonate, with the purpose of transporting CO_2 to HCO_3^- between tissue types, contributing to pH homeostasis, bone calcification and electrolyte transport, and ultimately participate in biogenic routes/processes, such as lipogenesis, ureagenesis or gluconeogenesis [131–133].

Several groups have independently used 2-phenethylamine based sulfamides and monothiocarbamates (Figure 8) as CA inhibitors, as frequently targeting a specific CA is related to a certain syndrome or disease, such as glaucoma [134], obesity [135], or certain types of cancer [136].




Figure 8. 2-Phenylethyl-based CA ligands.

Nocentini et al. tested phenethylamine monothiocarbamates **87** and **88** as well as other cyclic derivatives against human CA I/II (hCA), with 26–43 nM activities in type II (Figure 8a) [137]. Symmetric sulfamides were employed by Topal et al. (Figure 8b) with hCAI/II inhibition demonstrated at nanomolar level [138]. Branched sulfamides integrating the 1-phenyl-2-phenethylamine scaffold, elaborated by Akıncioğlu et al. [139] were found to be single-digit nanomolar inhibitors of both type I/II hCA (Figure 8c).

2.6. Dopamine β -Hydroxylase

Dopamine β -hydroxylase (DBH) is a Cu-based oxidoreductase that controls dopamine transformation into norepinephrine (Figure 2) in several neuron types (like adrenergic or noradrenergic ones) [140]. Limited studies have been developed on the use of modified 2-phenethylamines to target DBH. Kruse et al. [141] developed 2-vinyl- and 2-alkynyl-based 2-phenethylamines with moderate *in vitro* activities (Figure 9).




Figure 9. 2-Phenylethyl-based DBH ligands by Kruse et al [141].

More advanced DBH inhibitors are constituted by imidazolethione amines, such as etamicastat [142,143], nepicastat [144] or zamicastat [145], with low resemblance to dopaminergic amines.

2.7. Dipeptidyl Peptidases (DPP)

Dipeptidyl peptidases are exopeptidases responsible for proteolytic transformations, specifically cleaving the peptide bond after the penultimate proline residue. DPP4 is a serine protease displaying a critical role in cell adhesion, inflammation processes and immune regulation by deactivating GLP-1 and hence lowering blood glucose levels [146]. Type 2 diabetes is the main therapeutic area where DPP4 ligands have been discovered (Figures 10 and 11, Table 3).




Figure 10. 2-Phenylethyl-based DPP4 medicinal chemistry leads.




Figure 11. 2-Phenylethyl-based DPP4 receptor ligands.

Table 3. DPP4 medicinal chemistry leads.

Molecule	Name	Primary Targets	Secondary Targets	References
93	Evogliptin	DPP4		[147–149]
94	Nateglinide	DPP4		[150]
95	Retagliptin	DPP4		[151]
96	Sitagliptin	DPP4		[152,153]

Backes et al. [154] and Pei et al. [155] developed pyrrolidine-constrained and piperidine-constrained phenethylamines selectively targeting DPP4 with interesting PK profiles (Figure 11).

2.8. Dopamine Receptors (DX)

Dopamine receptors are a class of GPCR widely distributed in the brain, with key functionalities related to cognition, motivation and muscular drive. Pharmacologically, they are grouped into two families: D1-type (D1 and D5 receptors) and D2-type (D2S, D2L, D3 and D4) [156,157]. Medicinal chemistry of D1/D2-type receptor ligands addresses mainly the treatment of schizophrenia. From the chemical point of view concerning this review, a few small molecules presenting a basic 2-phenethylamine structure are reported in the literature (Figure 12, Table 4).

Table 4. Dopamine receptor medicinal chemistry leads.

Molecule	Name	Primary Targets	Secondary Targets	References
101	A-77636	D1		[158]
102	A68930	D1		[159]
103	Ansifaxine	D		[160]
104	Oxidopamine	D		[161]
105	Ropinirole	D2, D3, D4		[162]
106	5-OH-DPAT	D		[163]




Figure 12. 2-Phenylethyl-based dopamine receptor medicinal chemistry leads.

2.9. Dopamine Transporter (DAT)

The dopamine transporter receptor modulates the availability of released dopamine in the synaptic space by relocating it back into the presynaptic cell. It serves as a main target for recreational drugs as well as psychostimulant and antidepressant drugs. Classically, DAT ligands are classified in amphetamine-type and cocaine-type structures [164]. While cocaine-type molecules exert inhibitory binding to DAT, amphetamine-type ones are substrates that are effectively transported to the presynaptic neuron, stimulating efflux of cytosolic dopamine [165].

Amphetamine-type DAT ligands can be grouped in two families: amphetamine derivatives **107** and cathinone derivatives **114**. Amphetamines are 1-alkyl-2-phenethylamine derivatives **107** summarized below (Figure 13, Table 5). SAR attributes [166] are well known in this series, with diversification of the biological response with aryl substitutions, pharmacokinetic parameter shift upon alkylation of the amino group and decrease in dopaminergic pathways influenced by elongation of the alkyl chain at position 1. Due to being controlled substances in most countries, the number of compounds is constantly increasing, trying to avoid the introduction of compounds in the corresponding prohibition lists of each state [164,167]. Major concerns of this series are neurotoxicity, myocardial infarction, aneurysms, pulmonary hypertension, and tooth decay [168].

Table 5. Dopamine transporter classical binders.

Molecule	Name	References
108	Ephedrine	[169]
109	Amphetamine	[170]
110	Methamphetamine	[170]
111	MDMA	[170]
112	MBDB	[170]
113	MDEA	[170]
115	Cathinone	[170]
116	Methcathinone	[170]
117	Mephedrone	[170]
118	Pyrovalerone	[170]
119	Methylone	[170]
120	Ethylone	[170]




Figure 13. Amphetamine/cathinone-type families.

2.10. Galectin-1 Receptor

Galectins are a family of soluble carbohydrate binding proteins with several roles in inflammation, immune response, autophagy or signaling. Comprising 16 members, only 12 are expressed in humans [171]. Tejler et al. [172] described the synthesis of lactose derivatives, such as **121** with the phenethylamine moiety by 1,3-dipolar cycloadditions, with selective galectin-1 inhibition (Figure 14).




Figure 14. 2-Phenylethyl-based galectin-1 receptor ligands.

2.11. HIV-1 Reverse Transcriptase Receptor

Human immunodeficiency virus (HIV), origin of acquired immunodeficiency syndrome (AIDS), is a single-stranded (ss) RNA virus whose infection and propagation mechanisms requires reverse transcription into double-stranded (ds) DNA as a critical stage [173]. HIV-1 reverse transcriptase receptor (HIV-1 RT) is a well-explored target for antiretroviral therapies [174].

Venkatachalam et al. [175] designed a library of phenethyl thiourea compounds with good potency against HIV-1 RT inhibition without any evidence of cytotoxicity [175–177]. Eventually (Figure 15), these derivatives evolve in the phenethylthiazolylthiourea (PETT) family, with trovirdine as its prominent inhibitor [178–180].




Figure 15. 2-Phenylethyl-based HIV-1 RT receptor ligands.

2.12. 5-Hydroxytryptamine (5-HT) Receptors

5-Hydroxytryptamine (5-HT) receptors are one of the most extensively studied receptor families, with seven subtypes (5-HT₁, 5-HT₂, 5-HT₃, 5-HT₄, 5-HT₅, 5-HT₆, 5-HT₇) identified [181]. Therapeutic indications of 5-HT ligands and advanced leads (Figure 16, Table 6) cover different conditions, such as migraine, depression, social phobia, obsessive-compulsive disorder, anxiety, schizophrenia, eating disorders, panic-disorders, hypertension, pulmonary hypertension, emesis, vomiting, and irritable bowel syndrome (IBS) [182].




Figure 16. 2-Phenylethyl-based 5-HT medicinal chemistry leads.

Table 6. 5-HT medicinal chemistry leads.

Molecule	Name	Primary Targets	Secondary Targets	References
124	3-Hydroxy agomelatine	5-HT _{2C}		[183]
125	8-OH-DPAT	5-HT _{1A}		[184,185]
126	7-Desmethyl-3-hydroxyagomelatine	5-HT _{2C}	Melatonin MT1, MT2	[186]
127	Agomelatine	5-HT	Melatonin MT1, MT2	[187]
128	AR-A000002	5-HT _{1B}		[188]
129	AS19	5-HT ₇		[189,190]
130	Benzoctamine	5-HT		[191]
131	PCPA methyl ester	5-HT		[192]
132	U92016A	5-HT _{1A}		[193,194]

A novel class of 2-phenethylamines with hallucinogenic/psychedelic effects are N-benzylphenethylamines or NBOMes (**133**, **134**) (Figure 17) [195]. These agents have a selective binding profile towards 5-HT₂ receptor subtypes (5-HT_{2A}, 5-HT_{2B}, 5-HT_{2C}), making them promising therapeutic compounds. Traditionally, the assumption of converting the primary amine into a secondary one was associated with a prominent loss in 5-HT_{2A} activity. N-benzyl substitution was found to be the exception, increasing affinity and potency at the receptor [196]. SAR exploration of the NBOMes scaffold led to defining avoidable regions for SAR expansion, while mapping tolerated substitutions seeking potency/selectivity [197]. From the original 25X-NBOME halide derivatives [198], different derivatives have evolved.




Figure 17. NBOMes with 5-HT receptor activity.

Jensen et al. developed 25CN-NBOH (**135**) (Figure 17a) as a result of halide substitution by the cyano moiety, displaying high-picomolar/low-nanomolar binding affinities (competition binding assays with [³H]ketanserin) and functional potencies at 5-HT_{2A} receptor. Leth-Petersen et al. [199] designed a library of 25B-NBOME analogues **136**, such as **137** or **138** in the search of decreasing intrinsic clearance (Figure 17b). Despite the authors' efforts to decrease intrinsic clearance by lipophilicity reduction, no correlation was found, although several 5-HT₂ potent compounds were synthesized. Nichols et al. [200] explored the impact of methoxy and bromo scanning along the benzyl ring of 25I-NBOMe (**139**). Ortho or meta positions enhanced activity, whereas the para substitution reduced it. One of the best derivatives was **140**, which was compared with its tryptamine congener **141**, less potent overall in the 5-HT₂ assays performed (Figure 17c).

NBOMes and polyalkoxylated phenethylamines could be envisaged as mescaline (Figure 16, **142**) evolving structures. In this sense, significant efforts have been made to derive rational SAR maps together with attractive bioactive chemical matter [201]. Marcher-Rørsted et al. [202] reported the insertion of 2,5-dimethoxy motif in phenethylamine-like 5-HT_{2A} agonists. They demonstrated that this motif is relevant for in vivo potency, but without observed correlations in affinity or potency in competition binding assays (Figure 18a).

Oxygen-to-sulfur exchange reduces hallucinogenic-associated activity [203], while removal of one of the 2- or 5-position methoxy groups decreased in vivo activity [166]. Porter et al. [204] have derived 3-amino-chromanes and tetrahydroquinolines as selective 5-HT_{2B}/5-HT₇ ligands (Figure 18b). 5-HT_{2B} is not considered an optimal target, due to valvular heart disease and myofibroblast proliferation by long-term consumption of selective agonists [205,206]. 5-HT₇ is implicated in sleep, mood and circadian rhythm functions [207]. Kolaczynska et al. [208] analyzed the impact in 5-HT activity of 4-alkoxy exploration of 2,5-dimethoxyphenethylamines and amphetamines (Figure 18c). Both derivatives were found to interact strongly and selectively with 5-HT_{2A}, demonstrating that size and lipophilicity increase in this region favors 5-HT_{2A/C} affinity. Schultz et al. [209] and Nichols et al. [210] explored the fusion of furane/pyrane rings with the aromatic ring, as probes of the binding pocket size of 5-HT_{2A} receptor subtype and lone pair suitable orientation of the 2,5-oxy substituents, furnishing nanomolar-range receptor affinities (Figure 18d). McLean et al. [211] portrayed the conformationally restriction of 2-phenethylamines via 1-aminomethylbenzo cycloalkanes syntheses (Figure 18e). Benzocyclobutene derivative **153**'s strong potency against 5-HT_{2A} showed the hypothesis that the side chain of the phenethylamine binds in an out-of-the-plane conformation. Some of these conformationally restricted phenethylamines exhibit affinity for muscarinic receptors [212].




Figure 18. 2-Phenethylamines with 5-HT receptor activity.

2.13. Monoamine Oxidase (MAO) Receptors

Monoamine oxidases (MAO) are flavin-containing enzymes that catalyze the oxidative deamination of monoamines, which are bound to the outer membrane of mitochondria. Common MAO substrates are 5-hydroxy-tryptamine and catecholamines (dopamine, norepinephrine and epinephrine). MAO A and MAO B are the two enzyme isoforms, sharing a 70% sequence identity and differentiating each other in the substrate scope [213]. Theoretical approaches to rationalize isoform selection by substrates have been described [214,215]. As these two oxidases are responsible for neurotransmitter inactivation by oxidation, their dysfunction drives several neurological disorders, hence the therapeutic attractiveness (Figure 19, Table 7).




Figure 19. 2-Phenethylamine MAO medicinal chemistry leads.

Table 7. MAO medicinal chemistry leads.

Molecule	Name	Primary Targets	Secondary Targets	References
155	Amiflamine	MAO A		[216]
156	2-PAT	MAO A, B		[217]
157	GSK-LSD1	MAO	Lysine specific demethylase 1 (LSD1)	[218]
158	OG-L002	MAO A, B		[219]
159	Pheniprazine	MAO		[220]
160	Tranylcypromine	MAO		[221]
161	Vafidemstat	MAO B	Lysine specific demethylase 1 (LSD1)	[222]

2.14. Opioid Receptors

Opioid receptors are a class of GPCR proteins consisting of three receptor types, mainly μ -, δ -, and κ -types, with a variety of functional roles in the nervous system, such as pain signaling, growth, respiration, and immunological response [223,224]. Opioid ligands modulate neuronal inhibition and ultimately analgesia. Relevant side effects are well known, such as constipation or drug dependence/abuse.

Takahashi et al. [225–230] derived a small series of flexible 2-phenethylamines with analgesic activities, with moderate potency effects when compared with pentazocine or morphine (Figure 20a). Manchado et al. [231] developed quick asymmetric routes furnishing this type of derivative. Spetea et al. [232] developed selective diphenethylamine-based tertiary amines as κ -opioid receptors with 100-fold and 1000-fold selectivity difference compared with its congeners (Figure 20b).




Figure 20. 2-Phenethylamines with 5-HT receptor activity.

2.15. Peroxisome Proliferator-Activated (PPAR) Receptors

Peroxisome proliferator-activated (PPAR) receptors are peroxisome receptors and sub-cellular organelles performing several tasks related to cholesterol and fatty acid metabolism. Three members, named PPAR- α , PPAR- δ , and PPAR- γ , form this family, with different levels of expression and functionalities in diverse tissues, from energy storage in endothelial and vascular smooth muscle cells (type γ) to energy expenditure across all bodies (type δ). Several agents have been developed in relation to PPAR to address obesity, inflammation or neurodegenerative disorders (Figure 21, Table 8) [233,234].





Figure 21. 2-Phenethylamine PPAR medicinal chemistry leads.

Table 8. PPAR medicinal chemistry leads.

Molecule	Name	Primary Targets	Secondary Targets	References
169	Bezafibrate	PPAR		[235,236]
170	Chiglitazar	PPAR		[237]
171	Farglitazar	PPAR- γ		[238]
172	GW 9578	PPAR- α		[239]
173	GW1929	PPAR- γ		[240]
174	GW6471	PPAR- α		[241]
175	GW7647	PPAR- α		[242]

2.16. Sigma Receptors

Initially described as opioid receptors, sigma receptors conform their own family, unrelated to other receptors. Both members σ 1R and σ 2R are primarily found at the endoplasmic reticulum, and participate in diverse conditions, such as cancer, pain, neurodegenerative diseases or depression [243]. BD-1047 (Figure 22) is an open-chain, flexible 2-phenethylamine acting as antagonist of σ 1R [244].




176, BD-1047


Figure 22. A 2-Phenethylamine Sigma-1 receptor hit.

2.17. Trace Amine-Associated Receptors (TAAR)

Relatively recently discovered, trace amine-associated receptors (TAAR) are a GPCR family composed of nine members (TAAR1 to 9) with prospective therapeutic applications in the field of schizophrenia and metabolic disorders [245]. Lewin et al. [246] carried out SAR explorations with simple 2-phenethylamines to envisage improved pharmacological hits (Figure 23).



177, R₁=H or Me
R₂=H or Me
R₃=H, F, Cl or Br
R₄=H, F, Cl or Br
R₅=H, F, Cl or Br



178, EC₅₀ hTAAR1=65 nM

Figure 23. 2-Phenethylamines with hTAAR1 bioactivity.

3. Methods

All described compounds, targets and activities were retrieved using “2-phenethylamine” as title or keyword term in the chemical databases SciFinder [247] and Scopus [248]. Additionally, a SciFinder and Scopus structure search, with the scope described early in this review (Figure 2), was employed.

4. Conclusions

This review represents a concise, central summary of relevant 2-phenethylamine-based leads and research hits, which spans receptors and their corresponding therapeutic indications. This report serves as a guide to researchers interested in medicinal chemistry to identify suitable ligand–target associations displaying the aforementioned motif, as well as help to identify prospective targets of brand-new molecules with the 2-phenethylamine core embedded.

Future directions will include both a complementary report covering synthetic strategies to access 2-phenethylamine derivatives and a second, satellite review of 2-heteroaryl-ethylamines in medicinal chemistry.

Author Contributions: Conceptualization, C.T.N., A.M., L.B., D.D. and N.M.G.; investigation, C.T.N., A.M. and L.B.; data curation, C.T.N., A.M. and L.B.; writing—original draft preparation, C.T.N.; writing—review and editing, C.T.N., A.M., L.B., D.D. and N.M.G. All authors have read and agreed to the published version of the manuscript.

Funding: The authors gratefully acknowledge the financial support of this work provided by Ministerio de Ciencia e Innovación (PID2020-118303GB-I00/MCIN/AEI/10.13039/501100011033) and Junta de Castilla y Leon (SA0076P20). C.T.N. thanks Junta de Castilla y Leon for a postdoctoral contract (SA0076P20).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Chinta, S.J.; Andersen, J.K. Dopaminergic neurons. *Int. J. Biochem. Cell Biol.* **2005**, *37*, 942–946. [[CrossRef](#)]
2. Dean, B.V.; Stellpflug, S.J.; Burnett, A.M.; Engebretsen, K.M. 2C or Not 2C: Phenethylamine Designer Drug Review. *J. Med. Toxicol.* **2013**, *9*, 172–178. [[CrossRef](#)]
3. Kronstrand, R.; Guerrieri, D.; Vikingsson, S.; Wohlfarth, A.; Gréen, H. Fatal Poisonings Associated with New Psychoactive Substances. In *New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology*; Maurer, H.H., Brandt, S.D., Eds.; Springer International Publishing: Cham, Switzerland, 2018; pp. 495–541.
4. Grecco, G.G.; Sprague, J.E. Impact of Functional Group Modifications on Designer Phenethylamine Induced Hyperthermia. *Chem. Res. Toxicol.* **2016**, *29*, 871–878. [[CrossRef](#)] [[PubMed](#)]
5. Inan, F.; Brunt, T.M.; Contrucci, R.R.; Hondebrink, L.; Franssen, E.J.F. Novel Phenethylamines and Their Potential Interactions With Prescription Drugs: A Systematic Critical Review. *Ther. Drug. Monit.* **2020**, *42*, 271–281. [[CrossRef](#)] [[PubMed](#)]
6. Cocchi, V.; Gasperini, S.; Hrelia, P.; Tirri, M.; Marti, M.; Lenzi, M. Novel Psychoactive Phenethylamines: Impact on Genetic Material. *Int. J. Mol. Sci.* **2020**, *21*, 9616. [[CrossRef](#)]
7. Sogos, V.; Caria, P.; Porcedda, C.; Mostallino, R.; Piras, F.; Miliano, C.; De Luca, M.A.; Castelli, M.P. Human Neuronal Cell Lines as An In Vitro Toxicological Tool for the Evaluation of Novel Psychoactive Substances. *Int. J. Mol. Sci.* **2021**, *22*, 6785. [[CrossRef](#)]
8. Nagai, F.; Nonaka, R.; Satoh Hisashi Kamimura, K. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. *Eur. J. Pharmacol.* **2007**, *559*, 132–137. [[CrossRef](#)] [[PubMed](#)]
9. Jacobson, K.A.; Gao, Z.-G. Adenosine ☆. In *Reference Module in Neuroscience and Biobehavioral Psychology*; Elsevier: Amsterdam, The Netherlands, 2017.
10. Ballesteros-Yáñez, I.; Castillo, C.A.; Merighi, S.; Gessi, S. The Role of Adenosine Receptors in Psychostimulant Addiction. *Front. Pharmacol.* **2018**, *8*, 985. [[CrossRef](#)]
11. Masino, S.A.; Kawamura, M.; Ruskin, D.N. Chapter Eleven—Adenosine Receptors and Epilepsy: Current Evidence and Future Potential. In *International Review of Neurobiology*; Mori, A., Ed.; Academic Press: New York, NY, USA, 2014; pp. 233–255.
12. van Calker, D.; Biber, K.; Domschke, K.; Serchov, T. The role of adenosine receptors in mood and anxiety disorders. *J. Neurochem.* **2019**, *151*, 11–27. [[CrossRef](#)]
13. Tchilibon, S.; Kim, S.-K.; Gao, Z.-G.; Harris, B.A.; Blaustein, J.B.; Gross, A.S.; Duong, H.T.; Melman, N.; Jacobson, K.A. Exploring distal regions of the A3 adenosine receptor binding site: Sterically constrained N6-(2-phenylethyl)adenosine derivatives as potent ligands. *Biorg. Med. Chem.* **2004**, *12*, 2021–2034. [[CrossRef](#)]
14. Borowicz, K.K.; Kleinrok, Z.; Czuczwar, S.J. N6-2-(4-Aminophenyl)ethyl-adenosine enhances the anticonvulsive action of conventional antiepileptic drugs in the kindling model of epilepsy in rats. *Eur. Neuropsychopharmacol.* **2000**, *10*, 237–243. [[CrossRef](#)] [[PubMed](#)]
15. Borowicz, K.K.; Kleinrok, Z.; Czuczwar, S.J. N6-2-(4-Aminophenyl)ethyl-adenosine enhances the anticonvulsive activity of antiepileptic drugs. *Eur. J. Pharmacol.* **1997**, *327*, 125–133. [[CrossRef](#)] [[PubMed](#)]
16. Bao, R.; Shui, X.; Hou, J.; Li, J.; Deng, X.; Zhu, X.; Yang, T. Adenosine and the adenosine A2A receptor agonist, CGS21680, upregulate CD39 and CD73 expression through E2F-1 and CREB in regulatory T cells isolated from septic mice. *Int. J. Mol. Med.* **2016**, *38*, 969–975. [[CrossRef](#)]
17. Komaki, S.; Ishikawa, K.; Arakawa, Y. Trk and cAMP-dependent survival activity of adenosine A2A agonist CGS21680 on rat motoneurons in culture. *Neurosci. Lett.* **2012**, *522*, 21–24. [[CrossRef](#)] [[PubMed](#)]
18. Melani, A.; Corti, F.; Cellai, L.; Giuliana Vannucchi, M.; Pedata, F. Low doses of the selective adenosine A2A receptor agonist CGS21680 are protective in a rat model of transient cerebral ischemia. *Brain Res.* **2014**, *1551*, 59–72. [[CrossRef](#)]
19. Zhang, M.; Li, X.-L.; Li, H.; Wang, S.; Wang, C.-C.; Yue, L.-T.; Xu, H.; Zhang, P.; Chen, H.; Yang, B.; et al. Activation of the adenosine A2A receptor exacerbates experimental autoimmune neuritis in Lewis rats in association with enhanced humoral immunity. *J. Neuroimmunol.* **2016**, *293*, 129–136. [[CrossRef](#)]

20. Ludwig, S.; Hong, C.-S.; Razzo, B.M.; Fabian, K.P.L.; Chelvanambi, M.; Lang, S.; Storkus, W.J.; Whiteside, T.L. Impact of combination immunochemotherapies on progression of 4NQO-induced murine oral squamous cell carcinoma. *Cancer Immunol. Immunother.* **2019**, *68*, 1133–1141. [CrossRef]
21. Poucher, S.M.; Keddie, J.R.; Singh, P.; Stoggall, S.M.; Caulkett, P.W.R.; Jones, G.; Collis, M.G. The in vitro pharmacology of ZM 241385, a potent, non-xanthine, A2a selective adenosine receptor antagonist. *Br. J. Pharmacol.* **1995**, *115*, 1096–1102. [CrossRef]
22. Wang, Z.; Che, P.-L.; Du, J.; Ha, B.; Yarema, K.J. Static Magnetic Field Exposure Reproduces Cellular Effects of the Parkinson's Disease Drug Candidate ZM241385. *PLoS ONE* **2010**, *5*, e13883. [CrossRef]
23. Murai, Y.; Masuda, K.; Ogasawara, Y.; Wang, L.; Hashidoko, Y.; Hatanaka, Y.; Iwata, S.; Kobayashi, T.; Hashimoto, M. Synthesis of Photoreactive 2-Phenethylamine Derivatives—Synthesis of Adenosine Derivatives Enabling Functional Analysis of Adenosine Receptors by Photoaffinity Labeling. *Eur. J. Org. Chem.* **2013**, *2013*, 2428–2433. [CrossRef]
24. Friedhoff, A.J.; Silva, R. Catecholamines. In *Encyclopedia of the Human Brain*; Ramachandran, V.S., Ed.; Academic Press: New York, NY, USA, 2002; pp. 595–602.
25. Vago, T.; Meroni, R.; Dagani, R.; Baldi, G.; Pagani, M.; Bevilacqua, M.; Norbiato, G. Characterization of α 2-adrenoceptor binding properties of imidazoline-like drugs, azoloazepine derivatives and β -phenethylamine-like drugs in human platelet membranes. *J. Pharm. Pharmacol.* **1985**, *37*, 593–596. [CrossRef] [PubMed]
26. Mottram, D.R.; Thakar, Y. The action and interaction of β -phenethylamines and imidazolines on prejunctional α 2-adrenoceptors of guinea-pig ileum in the presence of the non-competitive antagonist benextramine. *J. Pharm. Pharmacol.* **1984**, *36*, 668–672. [CrossRef] [PubMed]
27. Smith, H.E.; Burrows, E.P.; Mobley, P.L.; Robinson, S.E.; Sulser, F. Agonist effects of beta.-phenethylamines on the noradrenergic cyclic adenosine 3',5'-monophosphate generating system in rat limbic forebrain. Stereoisomers of p-hydroxynorephedrine. *J. Med. Chem.* **1977**, *20*, 978–981. [CrossRef] [PubMed]
28. Ghouri, M.S.K.; Haley, T.J. Alpha-Adrenergic Receptor-Blocking Properties of Six Phenethylamine Derivatives In Vitro. *J. Pharm. Sci.* **1969**, *58*, 760–761. [CrossRef] [PubMed]
29. Akinaga, J.; Lima, V.; Kiguti, L.R.d.A.; Hebeler-Barbosa, F.; Alcántara-Hernández, R.; García-Sáinz, J.A.; Pupo, A.S. Differential Phosphorylation, Desensitization, and Internalization of α 1A – Adrenoceptors Activated by Norepinephrine and Oxymetazoline. *Mol. Pharmacol.* **2013**, *83*, 870–881. [CrossRef] [PubMed]
30. Esbenshade, T.A.; Hamada, A.; Miller, D.D.; Feller, D.R. Effects of the stereochemical orientation of phenethylamines and imidazolines on α -adrenergic receptor-mediated dna synthesis in primary cultured rat hepatocytes. *Chirality* **1992**, *4*, 279–285. [CrossRef]
31. Katerinopoulos, H.E.; Tagmatarchis, N.; Zaponakis, G.; Kefalakis, N.; Kordatos, K.; Spyrikis, M.; Thermos, K. β -Alkoxy-substituted phenethylamines: A family of compounds potentially active at the dopamine and α -adrenergic receptors. *Eur. J. Med. Chem.* **1995**, *30*, 949–954. [CrossRef]
32. Olsson, O.A.T.; Ahlquist, B.; Gustafsson, B.; Persson, G. The Effects in Myometrial Preparations of D2343, a β 2-Adrenoceptor Agonist Possessing α 1-Receptor Blocking Qualities. *Acta Pharmacol. Toxicol.* **1984**, *55*, 391–397. [CrossRef]
33. Tuttle, R.R.; Mills, J. Dobutamine: Development of a new catecholamine to selectively increase cardiac contractility. *Circ. Res.* **1975**, *36*, 185–196. [CrossRef]
34. Tyrankiewicz, U.; Skorka, T.; Jablonska, M.; Petkow-Dimitrow, P.; Chlopicki, S. Characterization of the cardiac response to a low and high dose of dobutamine in the mouse model of dilated cardiomyopathy by MRI in vivo. *J. Magn. Reson. Imaging* **2013**, *37*, 669–677. [CrossRef]
35. Vallet, B.; Dupuis, B.; Chopin, C. Dobutamine: Mechanisms of action and use in acute cardiovascular pathology. *Ann. Cardiol. Angeiol.* **1991**, *40*, 397–402. Available online: <https://pubmed.ncbi.nlm.nih.gov/1859148/> (accessed on 10 January 2023).
36. Xu, C.; Ai, D.; Shi, D.; Suo, S.; Chen, X.; Yan, Y.; Cao, Y.; Zhang, R.; Sun, N.; Chen, W.; et al. Accurate Drug Repositioning through Non-tissue-Specific Core Signatures from Cancer Transcriptomes. *Cell Rep.* **2018**, *25*, 523–535.e5. [CrossRef] [PubMed]
37. Tsujimoto, G.; Timmins, P.V.; Hoffman, B.B. Alpha adrenergic receptors in the rabbit bladder base smooth muscle: Alpha-1 adrenergic receptors mediate contractile responses. *J. Pharmacol. Exp. Ther.* **1986**, *236*, 384. Available online: <https://jpet.aspetjournals.org/content/236/2/384.long> (accessed on 10 January 2023). [PubMed]
38. McPherson, G.A.; Summers, R.J. A Study Of α 1-adrenoceptors In Rat Renal Cortex: Comparison Of [3H]-prazosin Binding With The α 1-adrenoceptor Modulating Gluconeogenesis Under Physiological Conditions. *Br. J. Pharmacol.* **1982**, *77*, 177–184. [CrossRef] [PubMed]
39. Chiu, G.; Gluchowski, C.; Forray, C. Design and Synthesis of an α 1a-Adrenergic Receptor Subtype-Selective Antagonist from BE2254. *Chem. Biol. Drug Des.* **2006**, *67*, 437–439. [CrossRef] [PubMed]
40. Greenslade, F.C.; Tobia, A.J.; Madison, S.M.; Krider, K.M.; Newquist, K.L. Labetalol binding to specific alpha- and beta-adrenergic sites in vitro and its antagonism of adrenergic responses in vivo. *J. Mol. Cell. Cardiol.* **1979**, *11*, 803–811. [CrossRef]
41. Fox, G.R.; Virgo, B.B. The effects of phenobarbital, atropine, l- α -methyl dopa, and DL-propranolol on dieldrin-induced hyperglycemia in the adult rat. *Toxicol. Appl. Pharmacol.* **1985**, *78*, 342–350. [CrossRef]
42. Sweet, C.S. New centrally acting antihypertensive drugs related to methyl dopa and clonidine. *Hypertension* **1984**, *6*, II51. [CrossRef]
43. Orito, K.; Kishi, M.; Imaizumi, T.; Nakazawa, T.; Hashimoto, A.; Mori, T.; Kambe, T. α 2-adrenoceptor antagonist properties of OPC-28326, a novel selective peripheral vasodilator. *Br. J. Pharmacol.* **2001**, *134*, 763–770. [CrossRef]

44. Sumi, M.; Sata, M.; Hashimoto, A.; Imaizumi, T.; Yanaga, K.; Ohki, T.; Mori, T.; Nagai, R. OPC-28326, a selective femoral arterial vasodilator, augments ischemia induced angiogenesis. *Biomed. Pharmacother.* **2007**, *61*, 209–215. [[CrossRef](#)]
45. Minneman, K.P.; Theroux, T.L.; Hollinger, S.; Han, C.; Esbenshade, T.A. Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes. *Mol. Pharmacol.* **1994**, *46*, 929. Available online: <https://molpharm.aspetjournals.org/content/46/5/929/tab-article-info> (accessed on 10 January 2023).
46. Ford, A.P.D.W.; Daniels, D.V.; Chang, D.J.; Gever, J.R.; Jasper, J.R.; Lesnick, J.D.; Clarke, D.E. Pharmacological pleiotropism of the human recombinant α 1A-adrenoceptor: Implications for α 1-adrenoceptor classification. *Br. J. Pharmacol.* **1997**, *121*, 1127–1135. [[CrossRef](#)] [[PubMed](#)]
47. Rossi, M.; Roumeguère, T. Silodosin in the treatment of benign prostatic hyperplasia. *Drug Des. Dev. Ther.* **2010**, *4*, 291–297. [[CrossRef](#)]
48. Villa, L.; Buono, R.; Fossati, N.; Rigatti, P.; Montorsi, F.; Benigni, F.; Hedlund, P. Effects by silodosin on the partially obstructed rat ureter in vivo and on human and rat isolated ureters. *Br. J. Pharmacol.* **2013**, *169*, 230–238. [[CrossRef](#)]
49. Huang, Y.-T.; Lin, H.-C.; Chang, Y.-Y.; Yang, Y.-Y.; Lee, S.-D.; Hong, C.-Y.; Hong, C.-Y. Hemodynamic Effects of Synephrine Treatment in Portal Hypertensive Rats. *Jpn. J. Pharmacol.* **2001**, *85*, 183–188. [[CrossRef](#)] [[PubMed](#)]
50. Thomas, J.E.; Munir, J.A.; McIntyre, P.Z.; Ferguson, M.A. STEMI in a 24-year-old man after use of a synephrine-containing dietary supplement: A case report and review of the literature. *Tex. Heart Inst. J.* **2009**, *36*, 586–590. Available online: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2801940/> (accessed on 10 January 2023).
51. Chapple, C.; Andersson, K.-E. Tamsulosin: An overview. *World J. Urol.* **2002**, *19*, 397–404. [[CrossRef](#)]
52. Broad, J.; Callaghan, B.; Sanger, G.J.; Brock, J.A.; Furness, J.B. Analysis of the ghrelin receptor-independent vascular actions of ulimorelin. *Eur. J. Pharmacol.* **2015**, *752*, 34–39. [[CrossRef](#)] [[PubMed](#)]
53. Bylund, D.B. Beta Adrenoceptors*. In *xPharm: The Comprehensive Pharmacology Reference*; Enna, S.J., Bylund, D.B., Eds.; Elsevier: New York, NY, USA, 2007; pp. 1–7.
54. Hayward, L.F.; Mueller, P.J.; Hasser, E.M. Adrenergic Receptors. In *Encyclopedia of Endocrine Diseases*; Martini, L., Ed.; Elsevier: New York, NY, USA, 2004; pp. 112–115.
55. Wu, Y.; Zeng, L.; Zhao, S. Ligands of Adrenergic Receptors: A Structural Point of View. *Biomolecules* **2021**, *11*, 936. [[CrossRef](#)] [[PubMed](#)]
56. Bianchetti, A.; Manara, L. In vitro inhibition of intestinal motility by phenylethanolaminotetralines: Evidence of atypical β -adrenoceptors in rat colon. *Br. J. Pharmacol.* **1990**, *100*, 831–839. [[CrossRef](#)]
57. Simiand, J.; Keane, P.E.; Guitard, J.; Langlois, X.; Gonalons, N.; Martin, P.; Bianchetti, A.; Le Fur, G.; Soubrié, P. Antidepressant profile in rodents of SR 58611A, a new selective agonist for atypical β -adrenoceptors. *Eur. J. Pharmacol.* **1992**, *219*, 193–201. [[CrossRef](#)] [[PubMed](#)]
58. Abou-Mohamed, G.; Nagarajan, R.; Ibrahim, T.M.; Caldwell, R.W. Characterization of the adrenergic activity of arbutamine, a novel agent for pharmacological stress testing. *Cardiovasc. Drugs Ther.* **1996**, *10*, 39–47. [[CrossRef](#)] [[PubMed](#)]
59. Nagarajan, R.; Abou-Mohamed, G.; Myers, T.; Caldwell, R.W. A novel catecholamine, arbutamine, for a pharmacological cardiac stress agent. *Cardiovasc. Drug Ther.* **1996**, *10*, 31–38. [[CrossRef](#)] [[PubMed](#)]
60. Ruiz, M.; Takehana, K.; Petruzella, F.D.; Watson, D.D.; Beller, G.A.; Glover, D.K. Arbutamine stress perfusion imaging in dogs with critical coronary artery stenoses: (99m)Tc-sestamibi versus (201)Tl. *J. Nucl. Med.* **2002**, *43*, 664. Available online: <https://jnm.snmjournals.org/content/43/5/664.long> (accessed on 10 January 2023). [[PubMed](#)]
61. Sitar, D.S. Clinical Pharmacokinetics of Bambuterol. *Clin. Pharmacokinet.* **1996**, *31*, 246–256. [[CrossRef](#)]
62. Hughes, A.D.; Chen, Y.; Hegde, S.S.; Jasper, J.R.; Jaw-Tsai, S.; Lee, T.-W.; McNamara, A.; Pulido-Rios, M.T.; Steinfeld, T.; Mammen, M. Discovery of (R)-1-(3-((2-Chloro-4-(((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)amino)-3-oxopropyl)piperidin-4-yl [1,1'-Biphenyl]-2-ylcarbamate (TD-5959, GSK961081, Batefenterol): First-in-Class Dual Pharmacology Multivalent Muscarinic Antagonist and β 2 Agonist (MABA) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD). *J. Med. Chem.* **2015**, *58*, 2609–2622. [[CrossRef](#)]
63. Hegde, S.S.; Hughes, A.D.; Chen, Y.; Steinfeld, T.; Jasper, J.R.; Lee, T.-W.; McNamara, A.; Martin, W.J.; Pulido-Rios, M.T.; Mammen, M. Pharmacologic Characterization of GSK-961081 (TD-5959), a First-in-Class Inhaled Bifunctional Bronchodilator Possessing Muscarinic Receptor Antagonist and β 2-Adrenoceptor Agonist Properties. *J. Pharmacol. Exp. Ther.* **2014**, *351*, 190. [[CrossRef](#)]
64. Rasmussen, S.G.F.; Choi, H.-J.; Fung, J.J.; Pardon, E.; Casarosa, P.; Chae, P.S.; DeVree, B.T.; Rosenbaum, D.M.; Thian, F.S.; Kobilka, T.S.; et al. Structure of a nanobody-stabilized active state of the β 2 adrenoceptor. *Nature* **2011**, *469*, 175–180. [[CrossRef](#)] [[PubMed](#)]
65. Wu, C.; Cheng, W.; Sun, Y.; Dang, Y.; Gong, F.; Zhu, H.; Li, N.; Li, F.; Zhu, Z. Activating Brown Adipose Tissue for Weight Loss and Lowering of Blood Glucose Levels: A MicroPET Study Using Obese and Diabetic Model Mice. *PLoS ONE* **2014**, *9*, e113742. [[CrossRef](#)]
66. Sangiorgi, E.; Curatolo, M. Application of a sequential analytical procedure for the detection of the β -agonist brombuterol in bovine urine samples. *J. Chromatogr. Biomed.* **1997**, *693*, 468–478. [[CrossRef](#)] [[PubMed](#)]
67. Wang, R.; Zhang, W.; Wang, P.; Su, X. A paper-based competitive lateral flow immunoassay for multi β -agonist residues by using a single monoclonal antibody labelled with red fluorescent nanoparticles. *Microchim. Acta* **2018**, *185*, 191. [[CrossRef](#)]

68. Bloom, J.D.; Dutia, M.D.; Johnson, B.D.; Wissner, A.; Burns, M.G.; Largis, E.E.; Dolan, J.A.; Claus, T.H. Disodium (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316,243). A potent beta-adrenergic agonist virtually specific for beta.3 receptors. A promising antidiabetic and antiobesity agent. *J. Med. Chem.* **1992**, *35*, 3081–3084. [CrossRef]
69. Shin, W.; Okamatsu-Ogura, Y.; Matsuoka, S.; Tsubota, A.; Kimura, K. Impaired adrenergic agonist-dependent beige adipocyte induction in obese mice. *J. Vet. Med. Sci.* **2019**, *81*, 799–807. [CrossRef]
70. González-Antuña, A.; Rodríguez-González, P.; Centineo, G.; García Alonso, J.I. Simultaneous determination of seven beta-agonists in human and bovine urine by isotope dilution liquid chromatography–tandem mass spectrometry using compound-specific minimally ¹³C-labelled analogues. *J. Chromatogr. A* **2014**, *1372*, 63–71. [CrossRef]
71. Peng, T.A.O.; Zhang, F.S.; Yang, W.C.; Li, D.X.; Chen, Y.; Xiong, Y.H.; Wei, H.U.A.; Lai, W.H. Lateral-Flow Assay for Rapid Quantitative Detection of Clorprenaline Residue in Swine Urine. *J. Food Prot.* **2014**, *77*, 1824–1829. [CrossRef]
72. Nishio, R.; Matsumori, A.; Shioi, T.; Wang, W.; Yamada, T.; Ono, K.; Sasayama, S. Denopamine, a beta1-adrenergic agonist, prolongs survival in a murine model of congestive heart failure induced by viral myocarditis: Suppression of tumor necrosis factor-alpha production in the heart. *J. Am. Coll. Cardiol.* **1998**, *32*, 808–815. [CrossRef] [PubMed]
73. Bangash, M.N.; Patel, N.S.A.; Benetti, E.; Collino, M.; Hinds, C.J.; Thiemermann, C.; Pearse, R.M. Dopexamine can attenuate the inflammatory response and protect against organ injury in the absence of significant effects on hemodynamics or regional microvascular flow. *Crit. Care* **2013**, *17*, R57. [CrossRef] [PubMed]
74. Hosie, J.; Scott, A.K.; Petrie, J.C.; Cockshott, I.D. Pharmacokinetics of epanolol after acute and chronic oral dosing in elderly patients with stable angina pectoris. *Br. J. Clin. Pharmacol.* **1990**, *29*, 333–337. [CrossRef]
75. Wang, W.; Chen, J.; Li, X.G.; Xu, J. Anti-inflammatory activities of fenoterol through beta-arrestin-2 and inhibition of AMPK and NF-kappaB activation in AICAR-induced THP-1 cells. *Biomed. Pharmacother.* **2016**, *84*, 185–190. [CrossRef] [PubMed]
76. Heel, R.C.; Brogden, R.N.; Speight, T.M.; Avery, G.S. Fenoterol: A Review of its Pharmacological Properties and Therapeutic Efficacy in Asthma. *Drugs* **1978**, *15*, 3–32. [CrossRef]
77. Arnsten, A.F.; Jin, L.E. Guanfacine for the treatment of cognitive disorders: A century of discoveries at Yale. *Yale J. Biol. Med.* **2012**, *85*, 45–58. Available online: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3313539/> (accessed on 10 January 2023). [PubMed]
78. Gomi, Y.; Shirahase, H.; Funato, H. Effects of 1-(2-chloro-4-hydroxyphenyl)-t-butyl-aminoethanol (HOKU-81), A New Bronchodilator, on Isolated Trachea and Atria of Guinea Pig. *Jpn. J. Pharmacol.* **1979**, *29*, 515–524. [CrossRef] [PubMed]
79. Underwood, S.L.; Lewis, S.A.; Raeburn, D. RP 58802B, a long-acting beta2-adrenoceptor agonist: Assessment of antiasthma activity in the guinea-pig in vivo. *Pulm. Pharmacol.* **1992**, *5*, 203–212. [CrossRef] [PubMed]
80. Su Ui, L.; Kyung-Seop, A.; Min Hee, S.; Ji-Won, P.; Hyung Won, R.; Hyun-Jun, L.; Sung-Tae, H.; Sei-Ryang, O. Indacaterol Inhibits Tumor Cell Invasiveness and MMP-9 Expression by Suppressing IKK/NF-kappaB Activation. *Mol. Cells* **2014**, *37*, 585–591. [CrossRef]
81. Delpy, E.; Coste, H.; de Gouville, A.-C.L.M. Effects of cyclic GMP elevation on isoprenaline-induced increase in cyclic AMP and relaxation in rat aortic smooth muscle: Role of phosphodiesterase 3. *Br. J. Pharmacol.* **1996**, *119*, 471–478. [CrossRef] [PubMed]
82. Müller, F.U.; Boheler, K.R.; Eschenhagen, T.; Schmitz, W.; Scholz, H. Isoprenaline stimulates gene transcription of the inhibitory G protein alpha-subunit Gi alpha-2 in rat heart. *Circ. Res.* **1993**, *72*, 696–700. [CrossRef] [PubMed]
83. Vannucci, S.J.; Nishimura, H.; Satoh, S.; Cushman, S.W.; Holman, G.D.; Simpson, I.A. Cell surface accessibility of GLUT4 glucose transporters in insulin-stimulated rat adipose cells. Modulation by isoprenaline and adenosine. *Biochem. J.* **1992**, *288*, 325–330. [CrossRef] [PubMed]
84. Falkay, G.; Kovács, L. Affinity of tocolytic agents on human placental and myometrial beta-adrenergic receptors. *J. Perinat. Med.* **1986**, *14*, 109–113. [CrossRef]
85. Igawa, Y.; Schneider, T.; Yamazaki, Y.; Tatemichi, S.; Homma, Y.; Nishizawa, O.; Michel, M.C. Functional investigation of beta-adrenoceptors in human isolated detrusor focusing on the novel selective beta3-adrenoceptor agonist KUC-7322. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **2012**, *385*, 759–767. [CrossRef]
86. Tomiyama, Y.; Murakami, M.; Hayakawa, K.; Akiyama, K.; Yamazaki, Y.; Kojima, M.; Shibata, N.; Akahane, M. Pharmacological Profile of KUL-7211, a Selective beta-Adrenoceptor Agonist, in Isolated Ureteral Smooth Muscle. *J. Pharmacol. Sci.* **2003**, *92*, 411–419. [CrossRef]
87. Neidhold, S.; Eichhorn, B.; Kasper, M.; Ravens, U.; Kaumann, A.J. The function of alpha- and beta-adrenoceptors of the saphenous artery in caveolin-1 knockout and wild-type mice. *Br. J. Pharmacol.* **2007**, *150*, 261–270. [CrossRef]
88. Sato, M.; Hutchinson, D.S.; Evans, B.A.; Summers, R.J. The beta3-Adrenoceptor Agonist 4-[[[(Hexylamino)carbonyl]amino]-N-[4-[2-[[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]-phenyl]-benzenesulfonamide (L75507) and Antagonist (S)-N-[4-[2-[[[3-[3-(Acetamidomethyl)phenoxy]-2-hydroxypropyl]amino]-ethyl]phenyl]benzenesulfonamide (L748337) Activate Different Signaling Pathways in Chinese Hamster Ovary-K1 Cells Stably Expressing the Human beta3-Adrenoceptor. *Mol. Pharmacol.* **2008**, *74*, 1417–1428. [CrossRef] [PubMed]
89. Randall, M.J.; Kostin, S.F.; Burgess, E.J.; Hoyt, L.R.; Ather, J.L.; Lundblad, L.K.; Poynter, M.E. Anti-Inflammatory Effects of Levalbuterol-Induced 11beta-Hydroxysteroid Dehydrogenase Type 1 Activity in Airway Epithelial Cells. *Front. Endocrinol.* **2015**, *5*, 236. [CrossRef]

90. Kube, J.C.; Holland, B.P.; Word, A.B.; Allen, J.B.; Calvo-Lorenzo, M.; McKenna, D.; Vogel, G. Effects of various doses of lubabegron on calculated ammonia gas emissions, growth performance, and carcass characteristics of beef cattle during the last 56 days of the feeding period. *Transl. Anim. Sci.* **2021**, *5*, txab137. [[CrossRef](#)]
91. Jesudason, C.D.; Baker, J.E.; Bryant, R.D.; Fisher, J.W.; O'Farrell, L.S.; Gaich, G.A.; He, M.M.; Kahl, S.D.; Kriauciusas, A.V.; Heiman, M.L.; et al. Combination of a Beta Adrenoceptor Modulator and a Norepinephrine-Serotonin Uptake Inhibitor for the Treatment of Obesity. *ACS Med. Chem. Lett.* **2011**, *2*, 583–586. [[CrossRef](#)] [[PubMed](#)]
92. Bi, S.; Zhao, T.; Wang, Y.; Zhou, H. Study on the interactions of mapenterol with serum albumins using multi-spectroscopy and molecular docking. *Luminescence* **2016**, *31*, 372–379. [[CrossRef](#)] [[PubMed](#)]
93. Ibrahim, F.A.; Fathy, M.E.; Elmansi, H.M. Highly sensitive spectrofluorimetric method for rapid determination of orciprenaline in biological fluids and pharmaceuticals. *Luminescence* **2019**, *34*, 77–83. [[CrossRef](#)] [[PubMed](#)]
94. Noh, H.; Yu, M.R.; Kim, H.J.; Lee, J.H.; Park, B.-W.; Wu, I.H.; Matsumoto, M.; King, G.L. Beta 2-adrenergic receptor agonists are novel regulators of macrophage activation in diabetic renal and cardiovascular complications. *Kidney Int.* **2017**, *92*, 101–113. [[CrossRef](#)] [[PubMed](#)]
95. Takasu, T.; Ukai, M.; Sato, S.; Matsui, T.; Nagase, I.; Maruyama, T.; Sasamata, M.; Miyata, K.; Uchida, H.; Yamaguchi, O. Effect of (R)-2-(2-Aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl] Acetanilide (YM178), a Novel Selective β 3-Adrenoceptor Agonist, on Bladder Function. *J. Pharmacol. Exp. Ther.* **2007**, *321*, 642–647. [[CrossRef](#)]
96. Yanagisawa, T.; Sato, T.; Yamada, H.; Sukegawa, J.; Nunoki, K. Selectivity and Potency of Agonists for the Three Subtypes of Cloned Human β -Adrenoceptors Expressed in Chinese Hamster Ovary Cells. *Tohoku J. Exp. Med.* **2000**, *192*, 181–193. [[CrossRef](#)]
97. Two novel beta agonists compare favourably with salbutamol. *Inpharma Wkly.* **1992**, *820*, 6. [[CrossRef](#)]
98. Aparici, M.; Carcasona, C.; Ramos, I.; Montero, J.L.; Ota, R.; Ortiz, J.L.; Cortijo, J.; Puig, C.; Vilella, D.; De Alba, J.; et al. Pharmacological Profile of AZD8871 (LAS191351), a Novel Inhaled Dual M3 Receptor Antagonist β 2-Adrenoceptor Agonist Molecule with Long-Lasting Effects and Favorable Safety Profile. *J. Pharmacol. Exp. Ther.* **2019**, *370*, 127–136. [[CrossRef](#)]
99. Farooqui, T. Octopamine-Mediated Neuromodulation of Insect Senses. *Neurochem. Res.* **2007**, *32*, 1511–1529. [[CrossRef](#)]
100. Axelrod, J.; Saavedra, J.M. Octopamine. *Nature* **1977**, *265*, 501–504. [[CrossRef](#)] [[PubMed](#)]
101. Bouyssou, T.; Casarosa, P.; Naline, E.; Pestel, S.; Konetzki, I.; Devillier, P.; Schnapp, A. Pharmacological Characterization of Olodaterol, a Novel Inhaled β 2-Adrenoceptor Agonist Exerting a 24-Hour-Long Duration of Action in Preclinical Models. *J. Pharmacol. Exp. Ther.* **2010**, *334*, 53–62. [[CrossRef](#)] [[PubMed](#)]
102. Yi, C.; Xing, G.; Wang, S.; Li, X.; Liu, Y.; Li, J.; Lin, B.; Woo, A.Y.-H.; Zhang, Y.; Pan, L.; et al. Design, synthesis and biological evaluation of 8-(2-amino-1-hydroxyethyl)-6-hydroxy-1,4-benzoxazine-3(4H)-one derivatives as potent β 2-adrenoceptor agonists. *Biorg. Med. Chem.* **2020**, *28*, 115178. [[CrossRef](#)]
103. Hoffmann, K.J.; Skånberg, I.; Borg, K.O. Species differences in the metabolism of pamatolol, a cardioselective beta-Adrenoceptor antagonist. *Eur. J. Drug Metab. Pharmacokinet.* **1979**, *4*, 163–173. [[CrossRef](#)]
104. Glossop, P.A.; Lane, C.A.L.; Price, D.A.; Bunnage, M.E.; Lewthwaite, R.A.; James, K.; Brown, A.D.; Yeadon, M.; Perros-Huguet, C.; Trevethick, M.A.; et al. Inhalation by Design: Novel Ultra-Long-Acting β 2-Adrenoreceptor Agonists for Inhaled Once-Daily Treatment of Asthma and Chronic Obstructive Pulmonary Disease That Utilize a Sulfonamide Agonist Headgroup. *J. Med. Chem.* **2010**, *53*, 6640–6652. [[CrossRef](#)]
105. Fuso, L.; Mores, N.; Valente, S.; Malerba, M.; Montuschi, P. Long-Acting Beta-Agonists and their Association with Inhaled Corticosteroids in COPD. *Curr. Med. Chem.* **2013**, *20*, 1477–1495. [[CrossRef](#)]
106. Li, M.; Yang, H.; Li, S.; Zhao, K.; Li, J.; Jiang, D.; Sun, L.; Deng, A. Ultrasensitive and Quantitative Detection of a New β -Agonist Phenylethanolamine A by a Novel Immunochromatographic Assay Based on Surface-Enhanced Raman Scattering (SERS). *J. Agr. Food Chem.* **2014**, *62*, 10896–10902. [[CrossRef](#)]
107. Seifert, R. Pronethalol. In *xPharm: The Comprehensive Pharmacology Reference*; Enna, S.J., Bylund, D.B., Eds.; Elsevier: New York, NY, USA, 2007; pp. 1–3.
108. Seifert, R. Reproterol. In *xPharm: The Comprehensive Pharmacology Reference*; Enna, S.J., Bylund, D.B., Eds.; Elsevier: New York, NY, USA, 2007; pp. 1–5.
109. Canadian Preterm Labor Investigators Group. Treatment of Preterm Labor with the Beta-Adrenergic Agonist Ritodrine. *N. Engl. J. Med.* **1992**, *327*, 308–312. [[CrossRef](#)]
110. Iakovidis, D.; Malta, E.; McPherson, G.A.; Raper, C. In Vitro Activity Of Ro363, a β 1-adrenoceptor Selective Agonist. *Br. J. Pharmacol.* **1980**, *68*, 677–685. [[CrossRef](#)]
111. Wood, M.; Dubois, V.; Scheller, D.; Gillard, M. Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors. *Br. J. Pharmacol.* **2015**, *172*, 1124–1135. [[CrossRef](#)] [[PubMed](#)]
112. McMacken, G.; Cox, D.; Roos, A.; Müller, J.; Whittaker, R.; Lochmüller, H. The beta-adrenergic agonist salbutamol modulates neuromuscular junction formation in zebrafish models of human myasthenic syndromes. *Hum. Mol. Genet.* **2018**, *27*, 1556–1564. [[CrossRef](#)] [[PubMed](#)]
113. Johnson, M. Salmeterol. *Med. Chem. Rev.* **1995**, *15*, 225–257. [[CrossRef](#)] [[PubMed](#)]

114. Muzzin, P.; Boss, O.; Mathis, N.; Revelli, J.P.; Giacobino, J.P.; Willcocks, K.; Badman, G.T.; Cantello, B.C.; Hindley, R.M.; Cawthorne, M.A. Characterization of a new, highly specific, beta 3-adrenergic receptor radioligand, [3H]SB 206606. *Mol. Pharmacol.* **1994**, *46*, 357–363. Available online: <https://molpharm.aspetjournals.org/content/46/2/357.long> (accessed on 10 January 2023). [PubMed]
115. Ind, P.W.; Laitinen, L.; Laursen, L.; Wenzel, S.; Wouters, E.; Deamer, L.; Nystrom, P. Early clinical investigation of Viozan™ (sibenaadet HCI), a novel D2 dopamine receptor, β_2 -adrenoceptor agonist for the treatment of chronic obstructive pulmonary disease symptoms. *Respir. Med.* **2003**, *97*, S9–S21. [CrossRef] [PubMed]
116. Hicks, A.; McCafferty, G.P.; Riedel, E.; Aiyar, N.; Pullen, M.; Evans, C.; Luce, T.D.; Coatney, R.W.; Rivera, G.C.; Westfall, T.D.; et al. GW427353 (Solabegron), a Novel, Selective β_3 -Adrenergic Receptor Agonist, Evokes Bladder Relaxation and Increases Micturition Reflex Threshold in the Dog. *J. Pharmacol. Exp. Ther.* **2007**, *323*, 202–209. [CrossRef]
117. Sybertz, E.J.; Baum, T.; Pula, K.K.; Nelson, S.; Eynon, E.; Sabin, C. Studies on the Mechanism of the Acute Antihypertensive and Vasodilator Actions of Several β -Adrenoceptor Antagonists. *J. Cardiovasc. Pharmacol.* **1982**, *4*, 749–758. [CrossRef]
118. Stohs, S.J.; Preuss, H.G.; Shara, M. A Review of the Receptor-Binding Properties of p-Synephrine as Related to Its Pharmacological Effects. *Oxidative Med. Cell. Longev.* **2011**, *2011*, 482973. [CrossRef]
119. Kozłowska, H.; Szymaska, U.; Schlicker, E.; Malinowska, B. Atypical β -adrenoceptors, different from β_3 -adrenoceptors and probably from the low-affinity state of β_1 -adrenoceptors, relax the rat isolated mesenteric artery. *Br. J. Pharmacol.* **2003**, *140*, 3–12. [CrossRef]
120. Jacobsen, J.R.; Aggen, J.B.; Church, T.J.; Klein, U.; Pfeiffer, J.W.; Pulido-Rios, T.M.; Thomas, G.R.; Yu, C.; Moran, E.J. Multivalent design of long-acting β_2 -adrenoceptor agonists incorporating biarylamines. *Bioorg. Med. Chem. Lett.* **2014**, *24*, 2625–2630. [CrossRef] [PubMed]
121. Mohamed Ismail, N.A.; Ibrahim, M.; Mohd Naim, N.; Mahdy, Z.A.; Jamil, M.A.; Mohd Razi, Z.R. Nifedipine versus terbutaline for tocolysis in external cephalic version. *Int. J. Gynecol. Obstet.* **2008**, *102*, 263–266. [CrossRef] [PubMed]
122. Loureiro, J.A.; Andrade, S.; Ramalho, M.J.; Oliveira, N.; Pereira, M.C. The interaction of a β_2 adrenoceptor agonist drug with biomimetic cell membrane models: The case of terbutaline sulphate. *Life Sci.* **2021**, *285*, 119992. [CrossRef]
123. Yamaya, M.; Nishimura, H.; Nadine, L.; Kubo, H.; Ryoichi, N. Tulobuterol inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells. *Physiol. Rep.* **2013**, *1*. [CrossRef]
124. Kempford, R.; Norris, V.; Siederer, S. Vilanterol trifenate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. *Pulm. Pharmacol. Ther.* **2013**, *26*, 256–264. [CrossRef] [PubMed]
125. Slack, R.J.; Barrett, V.J.; Morrison, V.S.; Sturton, R.G.; Emmons, A.J.; Ford, A.J.; Knowles, R.G. In Vitro Pharmacological Characterization of Vilanterol, a Novel Long-Acting β_2 -Adrenoceptor Agonist with 24-Hour Duration of Action. *J. Pharmacol. Exp. Ther.* **2013**, *344*, 218–230. [CrossRef]
126. Gwee, M.C.E.; Nott, M.W.; Raper, C.; Rodger, I.W. Pharmacological actions of a new β -adrenoceptor agonist, MJ-9184–1, in anaesthetized cats. *Br. J. Pharmacol.* **1972**, *46*, 375–385. [CrossRef]
127. Waldeck, B. β -Adrenoceptor Agonists after Terbutaline. *Pharmacol. Toxicol.* **1995**, *77*, 25–29. [CrossRef]
128. Wada, Y.; Nakano, S.; Morimoto, A.; Kasahara, K.-I.; Hayashi, T.; Takada, Y.; Suzuki, H.; Niwa-Sakai, M.; Ohashi, S.; Mori, M.; et al. Discovery of Novel Indazole Derivatives as Orally Available β_3 -Adrenergic Receptor Agonists Lacking Off-Target-Based Cardiovascular Side Effects. *J. Med. Chem.* **2017**, *60*, 3252–3265. [CrossRef] [PubMed]
129. Hu, B.; Ellingboe, J.; Han, S.; Largis, E.; Mulvey, R.; Oliphant, A.; Sum, F.-W.; Tillett, J. (4-Piperidin-1-yl)phenyl Amides: Potent and Selective Human β_3 Agonists. *J. Med. Chem.* **2001**, *44*, 1456–1466. [CrossRef]
130. Sun, W.S.; Park, Y.S.; Yoo, J.; Park, K.D.; Kim, S.H.; Kim, J.-H.; Park, H.-J. Rational Design of an Indolebutanoic Acid Derivative as a Novel Aldose Reductase Inhibitor Based on Docking and 3D QSAR Studies of Phenethylamine Derivatives. *J. Med. Chem.* **2003**, *46*, 5619–5627. [CrossRef]
131. Genç, H.; Kalin, R.; Köksal, Z.; Sadeghian, N.; Kocyigit, U.M.; Zengin, M.; Gülçin, İ.; Özdemir, H. Discovery of Potent Carbonic Anhydrase and Acetylcholinesterase Inhibitors: 2-Aminoindan β -Lactam Derivatives. *Int. J. Mol. Sci.* **2016**, *17*, 1736. [CrossRef] [PubMed]
132. Kose, L.P.; Gulcin, İ.; Yıldırım, A.; Atmaca, U.; Çelik, M.; Alwasel, S.H.; Supuran, C.T. The human carbonic anhydrase isoenzymes I and II inhibitory effects of some hydroperoxides, alcohols, and acetates. *J. Enzym. Inhib. Med. Chem.* **2016**, *31*, 1248–1253. [CrossRef] [PubMed]
133. Artunç, T.; Çetinkaya, Y.; Göçer, H.; Gülçin, İ.; Menzek, A.; Şahin, E.; Supuran, C.T. Synthesis of 4-[2-(3,4-dimethoxybenzyl)cyclopentyl]-1,2-dimethoxybenzene Derivatives and Evaluations of Their Carbonic Anhydrase Isoenzymes Inhibitory Effects. *Chem. Biol. Drug Des.* **2016**, *87*, 594–607. [CrossRef]
134. Scozzafava, A.; Supuran, C.T. Glaucoma and the Applications of Carbonic Anhydrase Inhibitors. In *Carbonic Anhydrase: Mechanism, Regulation, Links to Disease, and Industrial Applications*; Frost, S.C., McKenna, R., Eds.; Springer: Dordrecht, The Netherlands, 2014; pp. 349–359.
135. Queen, A.; Khan, P.; Azam, A.; Hassan, I.M. Understanding the Role and Mechanism of Carbonic Anhydrase V in Obesity and its Therapeutic Implications. *Curr. Protein Pept. Sci.* **2018**, *19*, 909–923. [CrossRef] [PubMed]

136. Chen, F.; Licarete, E.; Wu, X.; Petrusca, D.; Maguire, C.; Jacobsen, M.; Colter, A.; Sandusky, G.E.; Czader, M.; Capitano, M.L.; et al. Pharmacological inhibition of Carbonic Anhydrase IX and XII to enhance targeting of acute myeloid leukaemia cells under hypoxic conditions. *J. Cell. Mol. Med.* **2021**, *25*, 11039–11052. [[CrossRef](#)]
137. Nocentini, A.; Vullo, D.; Del Prete, S.; Osman, S.M.; Alasmay, F.A.S.; AlOthman, Z.; Capasso, C.; Carta, F.; Gratteri, P.; Supuran, C.T. Inhibition of the β -carbonic anhydrase from the dandruff-producing fungus *Malassezia globosa* with monothiocarbamates. *J. Enzym. Inhib. Med. Chem.* **2017**, *32*, 1064–1070. [[CrossRef](#)]
138. Topal, F.; Aksu, K.; Gulcin, I.; Tümer, F.; Goksu, S. Inhibition Profiles of Some Symmetric Sulfamides Derived from Phenethylamines on Human Carbonic Anhydrase I, and II Isoenzymes. *Chem. Biodivers.* **2021**, *18*, e2100422. [[CrossRef](#)]
139. Akıncioğlu, A.; Kocaman, E.; Akıncioğlu, H.; Salmas, R.E.; Durdagi, S.; Gülçin, İ.; Supuran, C.T.; Göksu, S. The synthesis of novel sulfamides derived from β -benzylphenethylamines as acetylcholinesterase, butyrylcholinesterase and carbonic anhydrase enzymes inhibitors. *Bioorg. Chem.* **2017**, *74*, 238–250. [[CrossRef](#)]
140. Weinshenker, D. Dopamine Beta-Hydroxylase. In *xPharm: The Comprehensive Pharmacology Reference*; Enna, S.J., Bylund, D.B., Eds.; Elsevier: New York, NY, USA, 2007; pp. 1–15.
141. Kruse, L.I.; Kaiser, C.; DeWolf, W.E., Jr.; Chambers, P.A.; Goodhart, P.J.; Ezekiel, M.; Ohlstein, E.H. Beta-Substituted phenethylamines as high-affinity mechanism-based inhibitors of dopamine beta-hydroxylase. *J. Med. Chem.* **1988**, *31*, 704–706. [[CrossRef](#)] [[PubMed](#)]
142. Vaz-da-Silva, M.; Rocha, J.-F.; Lacroix, P.; Falcão, A.; Almeida, L.; Soares-da-Silva, P. Cardiac safety profile of etamicastat, a novel peripheral selective dopamine- β -hydroxylase inhibitor in non-human primates, human young and elderly healthy volunteers and hypertensive patients. *IJC Metab. Endocr.* **2015**, *7*, 10–24. [[CrossRef](#)]
143. Loureiro, A.I.; João Bonifácio, M.; Fernandes-Lopes, C.; Igreja, B.; Wright, L.C.; Soares-da-Silva, P. Etamicastat, a new dopamine- β -hydroxylase inhibitor, pharmacodynamics and metabolism in rat. *Eur. J. Pharmacol.* **2014**, *740*, 285–294. [[CrossRef](#)]
144. Beliaev, A.; Learmonth, D.A.; Soares-da-Silva, P. Synthesis and Biological Evaluation of Novel, Peripherally Selective Chromanyl Imidazolethione-Based Inhibitors of Dopamine β -Hydroxylase. *J. Med. Chem.* **2006**, *49*, 1191–1197. [[CrossRef](#)] [[PubMed](#)]
145. Bicker, J.; Alves, G.; Fortuna, A.; Soares-da-Silva, P.; Falcão, A. In vitro assessment of the interactions of dopamine β -hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein. *Eur. J. Pharm. Sci.* **2018**, *117*, 35–40. [[CrossRef](#)]
146. Gallwitz, B. Clinical Use of DPP-4 Inhibitors. *Front. Endocrinol.* **2019**, *10*, 389. [[CrossRef](#)] [[PubMed](#)]
147. Yoon, H.; Sung, J.H.; Song, M.J. Effects of the Antidiabetic Drugs Evogliptin and Sitagliptin on the Immune Function of CD26/DPP4 in Th1 Cells. *Biomol. Ther.* **2021**, *29*, 154–165. [[CrossRef](#)]
148. Tan, X.; Hu, J. Evogliptin: A new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes. *Expert Opin. Pharmacol.* **2016**, *17*, 1285–1293. [[CrossRef](#)]
149. Kim, T.-H.; Kim, M.-K.; Cheong, Y.-H.; Chae, Y.-N.; Lee, Y.; Ka, S.-O.; Jung, I.-H.; Shin, C.-Y.; Bae, E.J.; Son, M.-H. Hepatic role in an early glucose-lowering effect by a novel dipeptidyl peptidase 4 inhibitor, evogliptin, in a rodent model of type 2 diabetes. *Eur. J. Pharmacol.* **2016**, *771*, 65–76. [[CrossRef](#)]
150. Duffy, N.A.; Green, B.D.; Irwin, N.; Gault, V.A.; McKillop, A.M.; O'Harte, F.P.M.; Flatt, P.R. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: Nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1. *Eur. J. Pharmacol.* **2007**, *568*, 278–286. [[CrossRef](#)]
151. Cahn, A.; Cernea, S.; Raz, I. An update on DPP-4 inhibitors in the management of type 2 diabetes. *Expert Opin. Emerg. Drugs* **2016**, *21*, 409–419. [[CrossRef](#)] [[PubMed](#)]
152. Thomas, L.; Eckhardt, M.; Langkopf, E.; Tadayyon, M.; Himmelsbach, F.; Mark, M. (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors. *J. Pharmacol. Exp. Ther.* **2008**, *325*, 175–182. [[CrossRef](#)]
153. Kim, S.-J.; Nian, C.; Doudet, D.J.; McIntosh, C.H.S. Inhibition of Dipeptidyl Peptidase IV With Sitagliptin (MK0431) Prolongs Islet Graft Survival in Streptozotocin-Induced Diabetic Mice. *Diabetes* **2008**, *57*, 1331–1339. [[CrossRef](#)]
154. Backes, B.J.; Longenecker, K.; Hamilton, G.L.; Stewart, K.; Lai, C.; Kopecka, H.; von Geldern, T.W.; Madar, D.J.; Pei, Z.; Lubben, T.H.; et al. Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 2005–2012. [[CrossRef](#)]
155. Pei, Z.; Li, X.; von Geldern, T.W.; Longenecker, K.; Pireh, D.; Stewart, K.D.; Backes, B.J.; Lai, C.; Lubben, T.H.; Ballaron, S.J.; et al. Discovery and Structure–Activity Relationships of Piperidinone- and Piperidine-Constrained Phenethylamines as Novel, Potent, and Selective Dipeptidyl Peptidase IV Inhibitors. *J. Med. Chem.* **2007**, *50*, 1983–1987. [[CrossRef](#)] [[PubMed](#)]
156. Sibley, D.R.; Neve, K. D2 Dopamine Receptor*. In *xPharm: The Comprehensive Pharmacology Reference*; Enna, S.J., Bylund, D.B., Eds.; Elsevier: New York, NY, USA, 2007; pp. 1–13.
157. Martel, J.C.; Gatti McArthur, S. Dopamine Receptor Subtypes, Physiology and Pharmacology: New Ligands and Concepts in Schizophrenia. *Front. Pharmacol.* **2020**, *11*, 1003. [[CrossRef](#)]
158. Kebabian, J.W.; Britton, D.R.; DeNinno, M.P.; Perner, R.; Smith, L.; Jenner, P.; Schoenleber, R.; Williams, M. A-77636: A potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets. *Eur. J. Pharmacol.* **1992**, *229*, 203–209. [[CrossRef](#)] [[PubMed](#)]

159. Matsuyama, N.; Shibata, S.; Matoba, A.; Kudo, T.-A.; Danielsson, J.; Kohjitani, A.; Masaki, E.; Emala, C.W.; Mizuta, K. The dopamine D1 receptor is expressed and induces CREB phosphorylation and MUC5AC expression in human airway epithelium. *Respir. Res.* **2018**, *19*, 53. [[CrossRef](#)]
160. Zhang, R.; Li, X.; Shi, Y.; Shao, Y.; Sun, K.; Wang, A.; Sun, F.; Liu, W.; Wang, D.; Jin, J.; et al. The Effects of LPM570065, a Novel Triple Reuptake Inhibitor, on Extracellular Serotonin, Dopamine and Norepinephrine Levels in Rats. *PLoS ONE* **2014**, *9*, e91775. [[CrossRef](#)]
161. Sviglerova, J.; Kuncova, J.; Stengl, M. Chapter 7—Cardiovascular Models: Heart Secondarily Affected by Disease (Diabetes Mellitus, Renal Failure, Dysfunctional Sympathetic Innervation). In *Animal Models for the Study of Human Disease*, 2nd ed.; Conn, P.M., Ed.; Academic Press: New York, NY, USA, 2017; pp. 175–203.
162. Eden, R.J.; Costall, B.; Domeney, A.M.; Gerrard, P.A.; Harvey, C.A.; Kelly, M.E.; Naylor, R.J.; Owen, D.A.A.; Wright, A. Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. *Pharmacol. Biochem. Behav.* **1991**, *38*, 147–154. [[CrossRef](#)]
163. Ågren, R.; Stepniewski, T.M.; Zeberg, H.; Selent, J.; Sahlholm, K. Dopamine D2 Receptor Agonist Binding Kinetics—Role of a Conserved Serine Residue. *Int. J. Mol. Sci.* **2021**, *22*, 4078. [[CrossRef](#)] [[PubMed](#)]
164. Jitcá, G.; Ósz, B.E.; Tero-Vescan, A.; Vari, C.E. Psychoactive Drugs—From Chemical Structure to Oxidative Stress Related to Dopaminergic Neurotransmission. A Review. *Antioxidants* **2021**, *10*, 381. [[CrossRef](#)] [[PubMed](#)]
165. Vaughan, R.A.; Foster, J.D. Mechanisms of dopamine transporter regulation in normal and disease states. *Trends Pharmacol. Sci.* **2013**, *34*, 489–496. [[CrossRef](#)]
166. Shulgin, A.T.; Sargent, T.; Naranjo, C. Structure–Activity Relationships of One-Ring Psychotomimetics. *Nature* **1969**, *221*, 537–541. [[CrossRef](#)]
167. Abbruscato, T.J.; Trippier, P.C. DARK Classics in Chemical Neuroscience: Methamphetamine. *ACS Chem. Neurosci.* **2018**, *9*, 2373–2378. [[CrossRef](#)]
168. Yu, S.; Zhu, L.; Shen, Q.; Bai, X.; Di, X. Recent Advances in Methamphetamine Neurotoxicity Mechanisms and Its Molecular Pathophysiology. *Behav. Neurol.* **2015**, *2015*, 103969. [[CrossRef](#)] [[PubMed](#)]
169. Rickli, A.; Hoener, M.C.; Liechti, M.E. Monoamine transporter and receptor interaction profiles of novel psychoactive substances: Para-halogenated amphetamines and pyrovalerone cathinones. *Eur. Neuropsychopharm.* **2015**, *25*, 365–376. [[CrossRef](#)]
170. Simmler, L.; Buser, T.; Donzelli, M.; Schramm, Y.; Dieu, L.-H.; Huwyler, J.; Chaboz, S.; Hoener, M.; Liechti, M. Pharmacological characterization of designer cathinones in vitro. *Br. J. Pharmacol.* **2013**, *168*, 458–470. [[CrossRef](#)]
171. Johannes, L.; Jacob, R.; Leffler, H. Galectins at a glance. *J. Cell Sci.* **2018**, *131*, jcs208884. [[CrossRef](#)]
172. Tejler, J.; Tullberg, E.; Frejd, T.; Leffler, H.; Nilsson, U.J. Synthesis of multivalent lactose derivatives by 1,3-dipolar cycloadditions: Selective galectin-1 inhibition. *Carbohydr. Res.* **2006**, *341*, 1353–1362. [[CrossRef](#)]
173. Hu, W.-S.; Hughes, S.H. HIV-1 Reverse Transcription. *CSH Perspect. Med.* **2012**, *2*, a006882. [[CrossRef](#)] [[PubMed](#)]
174. Ha, B.; Larsen, K.P.; Zhang, J.; Fu, Z.; Montabana, E.; Jackson, L.N.; Chen, D.-H.; Puglisi, E.V. High-resolution view of HIV-1 reverse transcriptase initiation complexes and inhibition by NNRTI drugs. *Nat. Commun.* **2021**, *12*, 2500. [[CrossRef](#)]
175. Venkatachalam, T.K.; Uckun, F.M. Synthesis of Symmetrical and Asymmetrical Phenethyl Thiourea Compounds as Nonnucleoside Inhibitors of HIV-1 Reverse Transcriptase. *Synth. Commun.* **2005**, *35*, 2039–2056. [[CrossRef](#)]
176. Venkatachalam, T.K.; Sudbeck, E.A.; Uckun, F.M. Regiospecific synthesis, X-ray crystal structure and biological activities of 5-bromothiophenethyl thioureas. *Tetrahedron Lett.* **2001**, *42*, 6629–6632. [[CrossRef](#)]
177. Mao, C.; Sudbeck, E.A.; Venkatachalam, T.K.; Uckun, F.M. Structure-based drug design of non-nucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase. *Biochem. Pharmacol.* **2000**, *60*, 1251–1265. [[CrossRef](#)]
178. Zhang, H.; Vrang, L.; Bäckbro, K.; Lind, P.; Sahlberg, C.; Unge, T.; Öberg, B. Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives trovirdine and MSC-127. *Antivir. Res.* **1995**, *28*, 331–342. [[CrossRef](#)]
179. Bell, F.W.; Cantrell, A.S.; Hoegberg, M.; Jaskunas, S.R.; Johansson, N.G.; Jordan, C.L.; Kinnick, M.D.; Lind, P.; Morin, J.M., Jr. Phenethylthiazolethiourea (PETT) Compounds, a New Class of HIV-1 Reverse Transcriptase Inhibitors. 1. Synthesis and Basic Structure–Activity Relationship Studies of PETT Analogs. *J. Med. Chem.* **1995**, *38*, 4929–4936. [[CrossRef](#)] [[PubMed](#)]
180. Cantrell, A.S.; Engelhardt, P.; Högberg, M.; Jaskunas, S.R.; Johansson, N.G.; Jordan, C.L.; Kangasmetsä, J.; Kinnick, M.D.; Lind, P.; Morin, J.M.; et al. Phenethylthiazolylthiourea (PETT) Compounds as a New Class of HIV-1 Reverse Transcriptase Inhibitors. 2. Synthesis and Further Structure–Activity Relationship Studies of PETT Analogs. *J. Med. Chem.* **1996**, *39*, 4261–4274. [[CrossRef](#)]
181. Pithadia, A.B.; Jain, S.M. 5-Hydroxytryptamine Receptor Subtypes and their Modulators with Therapeutic Potentials. *J. Clin. Med. Res.* **2009**, *1*, 72. [[CrossRef](#)] [[PubMed](#)]
182. Hoyer, D. 5-Hydroxytryptamine Receptors. In *xPharm: The Comprehensive Pharmacology Reference*; Enna, S.J., Bylund, D.B., Eds.; Elsevier: New York, NY, USA, 2007; pp. 1–7.
183. Chagraoui, A.; Protais, P.; Filloux, T.; Mocaër, E. Agomelatine(S 20098) antagonizes the penile erections induced by the stimulation of 5-HT_{2C} receptors in Wistar rats. *Psychopharmacology* **2003**, *170*, 17–22. [[CrossRef](#)]
184. Naiman, N.; Lyon, R.A.; Bullock, A.E.; Rydelek, L.T.; Titeler, M.; Glennon, R.A. 2-(Alkylamino)tetralin derivatives: Interaction with 5-HT_{1A} serotonin binding sites. *J. Med. Chem.* **1989**, *32*, 253–256. [[CrossRef](#)] [[PubMed](#)]

185. Mori, T.; Uzawa, N.; Iwase, Y.; Masukawa, D.; Rahmadi, M.; Hirayama, S.; Hokazono, M.; Higashiyama, K.; Shioda, S.; Suzuki, T. Narcolepsy-like sleep disturbance in orexin knockout mice are normalized by the 5-HT_{1A} receptor agonist 8-OH-DPAT. *Psychopharmacology* **2016**, *233*, 2343–2353. [CrossRef] [PubMed]
186. Li, M.; Tang, F.; Xie, F.; Lv, Y.; Yu, P.; Liu, Z.; Cheng, Z. Development and validation a LC–MS/MS method for the simultaneous determination of agomelatine and its metabolites, 7-desmethyl-agomelatine and 3-hydroxy-agomelatine in human plasma: Application to a bioequivalence study. *J. Chromatogr. B* **2015**, *1003*, 60–66. [CrossRef] [PubMed]
187. Millan, M.J.; Gobert, A.; Lejeune, F.; Dekeyne, A.; Newman-Tancredi, A.; Pasteau, V.; Rivet, J.-M.; Cussac, D. The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine 2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways. *J. Pharmacol. Exp. Ther.* **2003**, *306*, 954–964. [CrossRef] [PubMed]
188. Ahlgren, C.; Eriksson, A.; Tellefors, P.; Ross, S.B.; Stenfors, C.; Malmberg, Å. In vitro characterization of AR-A000002, a novel 5-hydroxytryptamine_{1B} autoreceptor antagonist. *Eur. J. Pharmacol.* **2004**, *499*, 67–75. [CrossRef]
189. Perez-García, G.S.; Meneses, A. Effects of the potential 5-HT₇ receptor agonist AS 19 in an autoshaping learning task. *Behav. Brain Res.* **2005**, *163*, 136–140. [CrossRef]
190. Brenchat, A.; Romero, L.; García, M.; Pujol, M.; Burgueño, J.; Torrens, A.; Hamon, M.; Baeyens, J.M.; Buschmann, H.; Zamanillo, D.; et al. 5-HT₇ receptor activation inhibits mechanical hypersensitivity secondary to capsaicin sensitization in mice. *PAIN* **2009**, *141*, 239–247. [CrossRef]
191. Lippmann, W.; Pugsley, T.A. Effects Of Benzoctamine And Chlordiazepoxide On Turnover And Uptake Of 5-hydroxytryptamine In The Brain. *Br. J. Pharmacol.* **1974**, *51*, 571–575. [CrossRef]
192. Oh, D.-R.; Kim, Y.; Jo, A.; Choi, E.J.; Oh, K.-N.; Kim, J.; Kang, H.; Kim, Y.R.; Choi, C.Y. Sedative and hypnotic effects of Vaccinium bracteatum Thunb. through the regulation of serotonergic and GABAergic systems: Involvement of 5-HT_{1A} receptor agonistic activity. *Biomed. Pharmacother.* **2019**, *109*, 2218–2227. [CrossRef]
193. McCall, R.B.; Romero, A.G.; Bienkowski, M.J.; Harris, D.W.; McGuire, J.C.; Piercey, M.F.; Shuck, M.E.; Smith, M.W.; Svensson, K.A.; Schreur, P.J. Characterization of U-92016A as a selective, orally active, high intrinsic activity 5-hydroxytryptamine_{1A} agonist. *J. Pharmacol. Exp. Ther.* **1994**, *271*, 875–883. Available online: <https://jpet.aspetjournals.org/content/271/2/875.long> (accessed on 10 January 2023).
194. Romero, A.G.; Leiby, J.A.; McCall, R.B.; Piercey, M.F.; Smith, M.W.; Han, F. Novel 2-substituted tetrahydro-3H-benz[e]indolamines: Highly potent and selective agonists acting at the 5-HT_{1A} receptor as possible anxiolytics and antidepressants. *J. Med. Chem.* **1993**, *36*, 2066–2074. [CrossRef] [PubMed]
195. Braden, M.R.; Parrish, J.C.; Naylor, J.C.; Nichols, D.E. Molecular Interaction of Serotonin 5-HT_{2A} Receptor Residues Phe339^(6.51) and Phe340^(6.52) with Superpotent N-Benzyl Phenethylamine Agonists. *Mol. Pharmacol.* **2006**, *70*, 1956. [CrossRef] [PubMed]
196. Poulie, C.B.M.; Jensen, A.A.; Halberstadt, A.L.; Kristensen, J.L. DARK Classics in Chemical Neuroscience: NBOMes. *ACS Chem. Neurosci.* **2020**, *11*, 3860–3869. [CrossRef] [PubMed]
197. Nichols, D.E. Structure–Activity Relationships of Phenethylamine Hallucinogens. *J. Pharm. Sci.* **1981**, *70*, 839–849. [CrossRef]
198. Elbardisy, H.M.; Foster, C.W.; Marron, J.; Mewis, R.E.; Sutcliffe, O.B.; Belal, T.S.; Talaat, W.; Daabees, H.G.; Banks, C.E. Quick Test for Determination of N-Bombs (Phenethylamine Derivatives, NBOME) Using High-Performance Liquid Chromatography: A Comparison between Photodiode Array and Amperometric Detection. *ACS Omega* **2019**, *4*, 14439–14450. [CrossRef] [PubMed]
199. Leth-Petersen, S.; Petersen, I.N.; Jensen, A.A.; Bundgaard, C.; Bæk, M.; Kehler, J.; Kristensen, J.L. 5-HT_{2A}/5-HT_{2C} Receptor Pharmacology and Intrinsic Clearance of N-Benzylphenethylamines Modified at the Primary Site of Metabolism. *ACS Chem. Neurosci.* **2016**, *7*, 1614–1619. [CrossRef]
200. Nichols, D.E.; Sassano, M.F.; Halberstadt, A.L.; Klein, L.M.; Brandt, S.D.; Elliott, S.P.; Fiedler, W.J. N-Benzyl-5-methoxytryptamines as Potent Serotonin 5-HT₂ Receptor Family Agonists and Comparison with a Series of Phenethylamine Analogues. *ACS Chem. Neurosci.* **2015**, *6*, 1165–1175. [CrossRef]
201. Nichols, D.E. Structure–activity relationships of serotonin 5-HT_{2A} agonists. *WIREs Mem. Trans.* **2012**, *1*, 559–579. [CrossRef]
202. Marcher-Rørsted, E.; Halberstadt, A.L.; Klein, A.K.; Chatha, M.; Jademyr, S.; Jensen, A.A.; Kristensen, J.L. Investigation of the 2,5-Dimethoxy Motif in Phenethylamine Serotonin 2A Receptor Agonists. *ACS Chem. Neurosci.* **2020**, *11*, 1238–1244. [CrossRef]
203. Jacob, P., III; Shulgin, A.T. Sulfur analogs of psychotomimetic agents. 2. Analogs of (2,5-dimethoxy-4-methylphenyl)- and of (2,5-dimethoxy-4-ethylphenyl)isopropylamine. *J. Med. Chem.* **1983**, *26*, 746–752. [CrossRef]
204. Porter, M.R.; Xiao, H.; Wang, J.; Smith, S.B.; Topczewski, J.J. 3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT_{2B}, 5-HT₇, or σ ₁ Receptor Ligands. *ACS Med. Chem. Lett.* **2019**, *10*, 1436–1442. [CrossRef]
205. Roth, B.L. Drugs and Valvular Heart Disease. *N. Engl. J. Med.* **2007**, *356*, 6–9. [CrossRef] [PubMed]
206. Connolly, H.M.; Crary, J.L.; McGoan, M.D.; Hensrud, D.D.; Edwards, B.S.; Edwards, W.D.; Schaff, H.V. Valvular Heart Disease Associated with Fenfluramine–Phentermine. *N. Engl. J. Med.* **1997**, *337*, 581–588. [CrossRef]
207. Nichols, D.E.; Nichols, C.D. Serotonin Receptors. *Chem. Rev.* **2008**, *108*, 1614–1641. [CrossRef]
208. Kolaczynska, K.E.; Luethi, D.; Trachsel, D.; Hoener, M.C.; Liechti, M.E. Receptor Interaction Profiles of 4-Alkoxy-Substituted 2,5-Dimethoxyphenethylamines and Related Amphetamines. *Front. Pharmacol.* **2019**, *10*, 1423. [CrossRef] [PubMed]
209. Schultz, D.M.; Prescher, J.A.; Kidd, S.; Marona-Lewicka, D.; Nichols, D.E.; Monte, A. ‘Hybrid’ benzofuran–benzopyran congeners as rigid analogs of hallucinogenic phenethylamines. *Biorg. Med. Chem.* **2008**, *16*, 6242–6251. [CrossRef]

210. Nichols, D.E.; Snyder, S.E.; Oberlender, R.; Johnson, M.P.; Huang, X. 2,3-Dihydrobenzofuran analogs of hallucinogenic phenethylamines. *J. Med. Chem.* **1991**, *34*, 276–281. [CrossRef]
211. McLean, T.H.; Parrish, J.C.; Braden, M.R.; Marona-Lewicka, D.; Gallardo-Godoy, A.; Nichols, D.E. 1-Aminomethylbenzocycloalkanes: Conformationally Restricted Hallucinogenic Phenethylamine Analogues as Functionally Selective 5-HT_{2A} Receptor Agonists. *J. Med. Chem.* **2006**, *49*, 5794–5803. [CrossRef]
212. Monte, A.P.; Marona-Lewicka, D.; Lewis, M.M.; Mailman, R.B.; Wainscott, D.B.; Nelson, D.L.; Nichols, D.E. Substituted Naphthofurans as Hallucinogenic Phenethylamine–Ergoline Hybrid Molecules with Unexpected Muscarinic Antagonist Activity. *J. Med. Chem.* **1998**, *41*, 2134–2145. [CrossRef] [PubMed]
213. Gaweska, H.; Fitzpatrick, P.F. Structures and mechanism of the monoamine oxidase family. *Biomol. Concepts* **2011**, *2*, 365–377. [CrossRef]
214. Hudspith, L.; Shmam, F.; Dalton, C.F.; Princivale, A.; Turega, S.M. Neurotransmitter selection by monoamine oxidase isoforms, dissected in terms of functional groups by mixed double mutant cycles. *Org. Biomol. Chem.* **2019**, *17*, 8871–8877. [CrossRef] [PubMed]
215. Heuson, E.; Storgaard, M.; Huynh, T.H.V.; Charmantray, F.; Gefflaut, T.; Bunch, L. Profiling substrate specificity of two series of phenethylamine analogs at monoamine oxidase A and B. *Org. Biomol. Chem.* **2014**, *12*, 8689–8695. [CrossRef] [PubMed]
216. Vallejos, G.; Rezende, M.C.; Cassels, B.K. Charge-transfer interactions in the inhibition of MAO-A by phenylisopropylamines—A QSAR study. *J. Comput. Aid. Mol. Des.* **2002**, *16*, 95–103. [CrossRef] [PubMed]
217. Meiring, L.; Petzer, J.P.; Legoabe, L.J.; Petzer, A. The evaluation of N-propargylamine-2-aminotetralin as an inhibitor of monoamine oxidase. *Bioorg. Med. Chem. Lett.* **2022**, *67*, 128746. [CrossRef]
218. Purich, D.L. *The Inhibitor Index: A Desk Reference on Enzyme Inhibitors, Receptor Antagonists, Drugs, Toxins, Poisons and Therapeutic Leads*; CRC Press: Boca Raton, FL, USA, 2017.
219. Liang, Y.; Quenelle, D.; Vogel, J.L.; Mascaro, C.; Ortega, A.; Kristie, T.M. A Novel Selective LSD1/KDM1A Inhibitor Epigenetically Blocks Herpes Simplex Virus Lytic Replication and Reactivation from Latency. *mBio* **2013**, *4*, e00558-12. [CrossRef]
220. Horita, A. Beta-phenylisopropylhydrazine, A Potent And Long Acting Monoamine Oxidase Inhibitor. *J. Pharmacol. Exp. Ther.* **1958**, *122*, 176–181. Available online: <https://jpet.aspetjournals.org/content/122/2/176> (accessed on 10 January 2023).
221. Shimamoto, K.; Matsuo, T.; Hattori, K.; Honjo, T. Effects of Skf-385 And Reserpine on The Tissue Catecholamine Content in Rabbits. *Jpn. J. Pharmacol.* **1964**, *14*, 425–433. [CrossRef]
222. Antonijoan, R.M.; Ferrero-Cafiero, J.M.; Coimbra, J.; Puentes, M.; Martínez-Colomer, J.; Arévalo, M.I.; Mascaró, C.; Molinero, C.; Buesa, C.; Maes, T. First-in-Human Randomized Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the KDM1A Inhibitor Vafidemstat. *CNS Drugs* **2021**, *35*, 331–344. [CrossRef]
223. Stein, C. Opioid Receptors. *Annu. Rev. Med.* **2016**, *67*, 433–451. [CrossRef]
224. Sobczak, M.; Sałaga, M.; Storr, M.A.; Fichna, J. Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: Current concepts and future perspectives. *J. Gastroenterol* **2014**, *49*, 24–45. [CrossRef]
225. Takahashi, H.; Chida, Y.; Yoshii, T.; Suzuki, T.; Yanaura, S. Asymmetric α -Substituted Phenethylamines. VI.: Synthesis and Analgesic Activity of Optically Pure (R)- and (S)-N-Akyl-1-cyclohexyl-2-phenylethylamines. *Chem. Pharm. Bull.* **1986**, *34*, 2071–2077. [CrossRef]
226. Takahashi, H.; Chida, Y.; Higashiyama, K.; Onishi, H. Asymmetric α -Substituted Phenethylamines. V. Synthesis of Chiral 1-Alkyl-2-phenylethylamines via Grignard Reaction of 4-Phenyl-1, 3-oxazolidines. *Chem. Pharm. Bull.* **1985**, *33*, 4662–4670. [CrossRef]
227. Takahashi, H.; Chida, Y.; Suzuki, T.; Onishi, H.; Yanaura, S. Asymmetric α -Substituted Phenethylamines. IV. The Synthesis and Analgesic Activity of Optically Pure (S) and (R)-1-Cyclohexyl- and 1-Cyclohexenyl-2-phenylethylamines. *Chem. Pharm. Bull.* **1984**, *32*, 2714–2723. [CrossRef]
228. Takahashi, H.; Chida, Y.; Suzuki, T.; Yanaura, S.; Suzuki, Y.; Masuda, C. Asymmetric α -Substituted Phenethylamines. III. The Synthesis and Analgesic Activity of optically Pure (S)- and (R)-1-Aryl-2-phenylethylamines. *Chem. Pharm. Bull.* **1983**, *31*, 1659–1665. [CrossRef]
229. Suzuki, Y.; Takahashi, H. Asymmetric α -Substituted Phenethylamines. II. The Enantioselective Synthesis of 1-Aryl-2-phenylethylamines from L- and D-Amino Acids by Means of 1, 3-Asymmetric Induction. *Chem. Pharm. Bull.* **1983**, *31*, 31–40. [CrossRef]
230. Takahashi, H.; Suzuki, Y.; Inagaki, H. Asymmetric α -Substituted Phenethylamines. I. Synthesis of Optically Pure 1-Aryl-N-(2'-hydroxy-1'-isopropylethyl)-2-phenylethylamines. *Chem. Pharm. Bull.* **1982**, *30*, 3160–3166. [CrossRef]
231. Manchado, A.; García, M.; Salgado, M.M.; Díez, D.; Garrido, N.M. A novel Barton decarboxylation produces a 1,4-phenyl radical rearrangement domino reaction. *Tetrahedron* **2018**, *74*, 5240–5247. [CrossRef]
232. Spetea, M.; Berzetei-Gurske, I.P.; Guerrieri, E.; Schmidhammer, H. Discovery and Pharmacological Evaluation of a Diphenethylamine Derivative (HS665), a Highly Potent and Selective κ Opioid Receptor Agonist. *J. Med. Chem.* **2012**, *55*, 10302–10306. [CrossRef] [PubMed]
233. Tyagi, S.; Gupta, P.; Saini, A.; Kaushal, C.; Sharma, S. The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. *J. Adv. Pharma. Technol. Res.* **2011**, *2*, 236–240. [CrossRef]
234. Willson, T.M.; Brown, P.J.; Sternbach, D.D.; Henke, B.R. The PPARs: From Orphan Receptors to Drug Discovery. *J. Med. Chem.* **2000**, *43*, 527–550. [CrossRef]

235. Usui-Ouchi, A.; Ouchi, Y.; Ebihara, N. The peroxisome proliferator-activated receptor pan-agonist bezafibrate suppresses microvascular inflammatory responses of retinal endothelial cells and vascular endothelial growth factor production in retinal pigmented epithelial cells. *Int. Immunopharmacol.* **2017**, *52*, 70–76. [[CrossRef](#)] [[PubMed](#)]
236. Franko, A.; Neschen, S.; Rozman, J.; Rathkolb, B.; Aichler, M.; Feuchtinger, A.; Brachthäuser, L.; Neff, F.; Kovarova, M.; Wolf, E.; et al. Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice. *Mol. Metab.* **2017**, *6*, 256–266. [[CrossRef](#)] [[PubMed](#)]
237. He, B.K.; Ning, Z.Q.; Li, Z.B.; Shan, S.; Pan, D.S.; Ko, B.C.B.; Li, P.P.; Shen, Z.F.; Dou, G.F.; Zhang, B.L.; et al. In Vitro and In Vivo Characterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist. *PPAR Res.* **2012**, *2012*, 546548. [[CrossRef](#)] [[PubMed](#)]
238. Chen, L.; Yang, B.; McNulty, J.A.; Clifton, L.G.; Binz, J.G.; Grimes, A.M.; Strum, J.C.; Harrington, W.W.; Chen, Z.; Balon, T.W.; et al. GI262570, a Peroxisome Proliferator-Activated Receptor γ Agonist, Changes Electrolytes and Water Reabsorption from the Distal Nephron in Rats. *J. Pharmacol. Exp. Ther.* **2005**, *312*, 718–725. [[CrossRef](#)]
239. Brown, P.J.; Winegar, D.A.; Plunket, K.D.; Moore, L.B.; Lewis, M.C.; Wilson, J.G.; Sundseth, S.S.; Koble, C.S.; Wu, Z.; Chapman, J.M.; et al. A Ureido-Thioisobutyric Acid (GW9578) Is a Subtype-Selective PPAR α Agonist with Potent Lipid-Lowering Activity. *J. Med. Chem.* **1999**, *42*, 3785–3788. [[CrossRef](#)]
240. Brown, K.K.; Henke, B.R.; Blanchard, S.G.; Cobb, J.E.; Mook, R.; Kaldor, I.; Kliewer, S.A.; Lehmann, J.M.; Lenhard, J.M.; Harrington, W.W.; et al. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. *Diabetes* **1999**, *48*, 1415–1424. [[CrossRef](#)] [[PubMed](#)]
241. Xu, H.E.; Stanley, T.B.; Montana, V.G.; Lambert, M.H.; Shearer, B.G.; Cobb, J.E.; McKee, D.D.; Galardi, C.M.; Plunket, K.D.; Nolte, R.T.; et al. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPAR α . *Nature* **2002**, *415*, 813–817. [[CrossRef](#)] [[PubMed](#)]
242. Luo, M.; Yeruva, S.; Liu, Y.; Chodisetti, G.; Riederer, B.; Menon, M.B.; Tachibana, K.; Doi, T.; Seidler, U.E. IL-1 β -Induced Down-regulation of the Multifunctional PDZ Adaptor PDZK1 Is Attenuated by ERK Inhibition, RXR α , or PPAR α Stimulation in Enterocytes. *Front. Physiol.* **2017**, *8*, 61. [[CrossRef](#)] [[PubMed](#)]
243. Aydar, E.; Cobos, E.J.; Maurice, T.; Murell-Lagnado, R.D.; Safrany, S.T. Editorial: Sigma Receptors. *Front. Pharmacol.* **2020**, *11*, 590519. [[CrossRef](#)] [[PubMed](#)]
244. Skuza, G.; Rogósz, Z. Effect of BD 1047, a sigma1 receptor antagonist, in the animal models predictive of antipsychotic activity. *Pharmacol. Rep.* **2006**, *58*, 626–635. Available online: http://www.if-pan.krakow.pl/pjp/pdf/2006/5_626.pdf (accessed on 10 January 2023). [[PubMed](#)]
245. Christian, S.L.; Berry, M.D. Trace Amine-Associated Receptors as Novel Therapeutic Targets for Immunomodulatory Disorders. *Front. Pharmacol.* **2018**, *9*, 680. [[CrossRef](#)] [[PubMed](#)]
246. Lewin, A.H.; Navarro, H.A.; Wayne Mascarella, S. Structure–activity correlations for β -phenethylamines at human trace amine receptor 1. *Biorg. Med. Chem.* **2008**, *16*, 7415–7423. [[CrossRef](#)] [[PubMed](#)]
247. CAS. SciFinder-n. 2023. Available online: <https://www.cas.org/solutions/cas-scifinder-discovery-platform/cas-scifinder> (accessed on 10 January 2023).
248. Elsevier B.V. Scopus. 2023. Available online: <https://www.elsevier.com/solutions/scopus> (accessed on 10 January 2023).

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.